

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Do Oral Contraceptives Affect Sleep among Women of Reproductive Age? A Systematic Review Protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-045819
Article Type:	Protocol
Date Submitted by the Author:	14-Oct-2020
Complete List of Authors:	Ma, Jinhui; McMaster University, Department of Health Research Methods, Evidence, and Impact Cheng, Megan; McMaster University Faculty of Health Sciences, Thabane, Lehana; McMaster University, Department of Health Research Methodology, Evidence, and Impact Ma, Caihong; Peking University Third Hospital, Zhang, Ning; Beijing Tiantan Hospital, Capital Medical University, Department of Neuropsychiatry and Behavioral Neurology ; Capital Medical University, Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Wang, Qi; McMaster University, Department of Health Research Methods, Evidence, and Impact Kim, Hyunwoo; McMaster University, Department of Health Research Methods, Evidence, and Impact Reza, Hameed; McMaster University, Faculty of Science Wang, Chunxue; Beijing Tiantan Hospital, Capital Medical University; Capital Medical University, 5Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Wang, Chunxue; Beijing Tiantan Hospital, Capital Medical University; Capital Medical University, 5Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Yao, Xiaomei; McMaster University, Department of Health Research Methods, Evidence and Impact; McMaster University, Department of Oncology
Keywords:	REPRODUCTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Do Oral Contraceptives Affect Sleep among Women of Reproductive Age? A Systematic Review Protocol

Jinhui Ma¹, Megan Cheng², Lehana Thabane¹, Caihong Ma³, Ning Zhang^{4,5}, Qi Wang¹, Hyunwoo Kim¹, Hameed Reza⁵, Chunxue Wang^{4,5}, Xiaomei Yao^{1,7}

¹Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

²Faculty of Health Science, McMaster University, Hamilton, Ontario, Canada

³Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking

University Third Hospital, Beijing, China

⁴Department of Neuropsychiatry and Behavioral Neurology, Beijing Tiantan Hospital, Capital

Medical University, Beijing, China

⁵Institute of sleep and consciousness disorders, Beijing Institute of Brain Disorders,

Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China

⁶Faculty of Science, McMaster University, Hamilton, Ontario, Canada

⁷Department of Oncology, McMaster University, Hamilton, Ontario, Canada

Corresponding:

Xiaomei Yao: 711 Concession Street, Hamilton, L8V 1C3, ON, Canada, Tel: +1-9055274322 ext. 42824, E-mail: <u>yaoxia@mcmaster.ca</u> Chunxue Wang: No. 119 South Fourth Ring West Road, Fengtai District, Beijing 100070, P.R.

China ,Tel: +01186-13701193710, E-mail: snowsen@126.com

ABSTRACT

Introduction Oral contraceptives (OC) are one of the most popular contraceptives worldwide. Research evidence indicates that the hormones used in OC may affect sleep in humans. However, it remains unclear whether OC use is associated with poor quality of sleep and sleep disorders among women. This systematic review aims to elucidate the relationship between OC use and sleep in women of reproductive age (15-49 years).

Methods This review will analyze data from randomised controlled trials and non-randomised comparative studies investigating the association between OC (second generation or further) and sleep-related outcomes. Review papers addressing the same research question among the same population will be included. A literature search will be performed using the MEDLINE, EMBASE and Cochrane CENTRAL databases.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Risk of bias will be assessed using The Cochrane Collaboration's revised tool for assessing risk of bias for randomised trials (RoB 2.0), The Cochrane Risk of Bias in Non-randomised studies – of Interventions (ROBINS-1 tool), and Risk of Bias in Systematic Reviews (ROBIS) tool. Two reviewers will independently assess eligibility of studies and risk of bias and extract the data. A third author will solve discrepancies. All extracted data will be presented in summary tables and in a narrative synthesis. For sleep measures investigated by three or more studies with low heterogeneity, we will conduct random-effects meta-analysis to estimate the magnitude of the overall effect of OC. The GRADE approach will be used to summarize the quality of evidence.

Ethics and dissemination Ethics approval is not required as we analyze data from previously reported studies.

PROSPERO registration number Pending.

Article Summary

Strengths and limitations of this study:

- This review on the association between oral contraceptive use and sleep is based on a robust, librarian consulted search strategy.
- All papers are screened by two independent reviewers to mitigate bias.
- The quality of all eligible papers will be assessed with the appropriate methodological tool.
- Papers in languages other than English are not included, leading to potential for language bias.

Keywords: Birth control; Oral contraceptives; Reproductive medicine; Sleep; Systematic review

Word Count: 3051

INTRODUCTION

Worldwide, there are around 1.9 billion women of reproductive age. One hundred and fiftyone million women use oral contraceptives (OC), with usage varying by region.¹ OC are used more widely in Europe and North America, especially in developed countries, than in developing countries. ¹ In 2019, 17.2% women of reproductive age in high-income countries, 6.7% in middleincome countries, and 3.8% in low-income countries used OC pills. ¹ The prevalence of OC usage worldwide has remained stable in the last 25 years, however, the overall number of users increased since the world population has increased.¹

The invention of OC is a medical innovation and OC have evolved dramatically in the past decades.² The first-generation OC pill, Enovid, contained high doses of norethynodrel (i.e., progestin, 10 mg) and mestranol (i.e., estrogen, 150µg) and was introduced in 1960. To lower the risk of thromboembolic complications associated with the use of OC pills, the second-generation of OC was developed in the 1970s by lowering the dose of the progestin component from 10 mg to 1 mg, and the estrogen component from 150µg to 35µg. Development of new progestins, mainly levonorgestrel, gave way to the second generation of OC, which contained a lower dosage of progesterone.³ The second-generation OC was shown to be associated with the androgenicity of the progestin. ⁴ Subsequently, the third generation of OC was developed in the 1990s to address side effects that arise due to the androgenicity of second generation progestins, such as acne and weight gain. ⁴ Fourth generation OC are more selective and bind specifically to the progesterone receptor, further reducing side effects such as edema and improving skin appearance. ⁵

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Progesterone, the primary component in OC, is an agonist of gamma-aminobutyric acid (GABA) receptors through a metabolite allopregnanolone. ⁶ GABA is a crucial molecule in sleep

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

promotion – most sleep-promoting neurons are sensitive to GABA.⁷ Common sleep medications, such as benzodiazepines have been shown to positively modulate GABA signalling.⁷ The potency of progestin is similar to that of benzodiazepines and has similar agonistic effects. Changes in electroencephalogram (EEG) activity seen with progesterone administration are similar to those evoked by benzodiazepines. ⁶ Studies in rat models have shown that administration of exogenous progesterone leads to dose-dependent decreased sleep latency and wakefulness. ⁶ The mechanism behind the effect of estrogen on sleep is not well elucidated but rat studies have shown that administration of exogen that administration of estrogen promotes sleep during the sleep period and reduces sleep during the wakefulness period.⁸ The overall effect on sleep is likely caused by a combination of both estrogen and progesterone, although the magnitude of their contribution to sleep changes is unknown.⁹

High quality sleep is as essential as regular exercise and eating a balanced diet for maintenance of optimal health and well-being. Severe sleeping problems, such as insomnia, are important matters from both a public health and individual perspective. Insomnia is associated with depression, anxiety, substance abuse, cognitive impairment, metabolic disorders (e.g., diabetes, dyslipidemia, and obesity) and cardiovascular diseases.¹⁰⁻¹² Women are more likely than men to have sleep problems including insomnia, restless leg syndrome, and sleep apnea since changing hormones during the menstrual cycle, pregnancy, and menopause can affect how well a woman sleeps.¹³⁻¹⁵ During ovulation, there is a surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which leads to a decrease in estrogen concentration and an increase in progesterone.¹⁶ During the luteal phase, progesterone concentrations increase and estrogen levels are high.¹⁶ Start from the mid-luteal phase, steroidal hormone levels decrease and women are awakened during sleep more often compared with the follicular phase.¹⁷ OC are taken each day for 21 days, providing a constant, exogenous source of estrogen and progesterone, preventing the

BMJ Open

release of FSH and LH and thus the production of a follicle or ovulation.¹⁷ Therefore, OC use may affect women's sleep-wake cycle and cause physiological change that lead to sleep disturbance.

Unlike other commonly prescribed drugs, OC pills are taken by healthy women for long periods of time. Safety trials have focused largely on breast cancer and venous thromboembolism (VTE) risk. ¹⁸⁻¹⁹ Despite decreases in estrogen concentration with later OC generations, its use has been shown to be associated with an increased risk of developing breast cancer and venous thromboembolism.⁴ A 2017 cohort study found OC intake was associated with a reduced risk of colorectal, endometrial and ovarian cancers and increased risk of cervical and breast cancer.²⁰ Another meta-analysis found a positive association between OC usage and risk of hypertension.²¹ Studies in women have varied findings on the association between OC use and sleep quality and duration. Differences in methodology, including the formulation of contraceptives taken, stratification of formulations, measurements of sleep, or the phase of the menstrual cycle of naturally cycling women used as comparison may explain the different findings between studies. For instance, a study published in 2020 by Guida *et al* found significantly increased sleep duration for users of oral progestins and gestodene, compared with naturally cycling women (women not currently using any hormonal contraceptive), as well as increased sleep latency in the oral levonorgestrel group. ²² However, a polysomnography study published in 2012 by Hachul et al found decreased sleep latency in women using OC and no difference in overall sleep quality.²³ A randomised control trial by Lundin *et al* found no significant sleep related results, while a cross sectional analysis by Bezerra *et al* found that hormonal contraceptive users had worse sleep quality compared with their naturally cycling counterparts.²⁴⁻²⁵

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Given the high prevalence of hormonal contraceptive use among women of reproductive age and the relationship between OC use and sleep varying in both magnitude and direction in the

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

current literature, there is an urgent need to provide women with accurate, evidence based information to inform their use of hormonal contraception.²²⁻²⁵ Hence, the objective of this systematic review is to compile and elucidate the association between OC use and sleep (including the quality of sleep, sleep disorders, and duration of sleep). Findings from this review will provide insights to women choosing between different methods and formulations, while also inform the development of new progestins for future generations of OC. The systematic review protocol was registered at the website of the International Prospective Register of Systematic Reviews (PROSPERO) with the registration number pending.

METHOD

Our protocol follows the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015) guidelines.²⁶

Literature search

We developed a comprehensive search strategy with input from a research librarian at McMaster University. The systematic search for existing relevant systematic review and original studies is conducted in the Ovid MEDLINE and Embase (Excerpta Medica dataBASE) electronic databases, and the Cochrane Library (including Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials). Search terms covered all words related to birth control, ingredients of oral contraceptives, and sleep. We limited the search to studies or systematic reviews published from 1970 to present to ensure that we include all published studies or reviewers on second and further generation OC. For sleep outcome measures, we searched sleep terms in the full text besides the title and abstract in case sleep is investigated as a secondary outcome and

BMJ Open

therefore not reported in the abstract. The comprehensive search strategies for each database are presented in Table 1.

Study Selection and Screening

Systematic screening of the studies will be first conducted at the title and abstract level, and then at the full-text level to determine if a study meets eligibility criteria by two independent reviewers. Any potential conflicts between the reviewers will be resolved through discussion. If discrepancies in judgment remain after discussion, a third-party reviewer will be consulted to resolve the conflict and provide a final decision.

Eligibility criteria

(1) Study Characteristics

Existing systematic reviews will be included if they (i) address the same research question with similar inclusion and exclusion criteria as ours; and (ii) have a low risk of bias in study eligibility criteria, identification and selection of studies, data collection and study appraisal, and synthesis and findings assessed using the Risk of Bias in Systematic Reviews (ROBIS) tool.²⁷

For original studies, we will include (i) randomised controlled trials and non-randomised comparative studies that take into account the effect of potential confounders (e.g., age, race, and socioeconomic status)²⁸⁻³⁰ using methods such as multivariable analysis, propensity-score matching, or showing no statistically significant differences in baseline characteristics between participants in comparison groups; (ii) studies on human participants; (iii) studies investigate second generation or more recent OC; and (iv) studies investigate the association between OC use and sleep-related outcomes, either as the primary or secondary objective.

(2) Participants

Participants or subgroups of participants are female, between 15 and 49 years old.

(3) Exposure

Participants or subgroups of participants take second generation or more recent OC, regardless of its brand, dose, frequency, and duration, to avoid pregnancy, as long as it contains hormonal ingredients.

(4) Comparator

Included studies must have comparison groups of women who are using (i) non-hormonal contraceptives; (ii) naturally cycling (i.e., not use any contraceptive methods); (iii) same agent as the exposure but in different dose, frequency, and duration; and (iv) second generation or more recent OC but different from the exposure.

(5) Outcomes

We are interested in any sleep-related outcomes and a variety of sleep measurements for sleep quality, sleep duration, and sleep disorder will be included in this systematic review. The sleep measurements can be questionnaires based on Likert Scale items listed below but not limited to these tools:

(i) The Pittsburgh Sleep Quality Index (PSQI). ³¹ It measures seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction over the last four weeks. The PSQI is a subjective measure of sleep. Subjects self-rate each of the seven domains of sleep from 0 to 3, where 3 represents the negative extreme on the Likert Scale. A subject with a global sum of 5 or greater is considered as a poor sleeper. Studies reported sleep quality in any of the above seven domains during and after taking OC will be included in the review.

Page 11 of 27

BMJ Open

- (ii) The Epworth Sleepiness Scale (ESS) is a self-administered test used to assess daytime sleepiness.³² It consists of 8 questions with different scenarios and a scale from 0-3 where subjects would indicate how likely they are to fall asleep in that situation. The scores are summed for a total score between 0 and 24. ³² Studies reporting sleepiness with any of the 8 questions during and after taking OC will be included in the review.
- (iii) The Athens Insomnia Scale (AIS), which is also a self-administered psychometric instrument designed for quantifying sleep difficulty.³³ The AIS consists of eight items: sleep induction (i.e., time to fall asleep after turning-off the lights), night awakenings, final awakening earlier than desired, total sleep duration, overall quality of sleep, sense of well-being during the day, functioning (physical and mental) during the day, and sleepiness during the day. Each item is rated from 0 to 3 with higher scores indicating more impaired sleep. The total score ranges from 0 to 24 and a total score of 6 or more is considered as insomnia. Studies reported any or all of the above eight insomnia-related items during and after taking OC will be included in the review.
- (iv) The Insomnia Severity Index (ISI), a self-administered questionnaire used to assess insomnia. ³⁴ The ISI consists has a one month recall period and assesses 7 domains: severity of sleep onset, sleep maintenance, difficultly waking up in the morning, sleep dissatisfaction, interference of sleep with daytime functioning, noticeability of sleep problems by others, and distress caused by sleep difficulties. Each domain is rated on a scale from 0 to 4 with higher scores indicating more problematic sleep. The score is summed forming a total score between 0 and 28, with a score of 8 and above indicative of insomnia. ³⁴ Studies reporting any domains from the ISI during and after taking OC will be included in the review.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

We will also include continuous measures of sleep quality and disorder. These measures include: (i) total amount of sleep obtained, either during nocturnal sleep episode or across the 24-hour period; (ii) sleep latency, i.e., how long it takes the participant to fall asleep; (iii) how many times do the participant wake up; (iv) how many minutes is the participant awake during the night; (v) sleep efficiency, i.e., what percentage of time spent in bed is the participant actually asleep. The total sleep time is equal to the total amount of time spent in bed (in minutes) minus the time it takes to fall asleep plus the time spent awake throughout the night. The percentage is calculated as the total sleep time divided by total time in bed.

Exclusion criteria

The following studies will be excluded from this systematic review: (1) studies only recruited patients with specific conditions (such as all patients with hypertension); (2) studies investigating the first-generation OC since it is not available in the market anymore due to severe side effects; (3) studies investigating emergency contraception; and (4) studies in languages other than English. We will exclude emergency contraception from this review as the hormonal effect of the contraception is significantly different from long-acting contraception. The half-life of estradiol is around 12 hours, which is not significant when considering long-term effect on sleep.³⁵

Data abstraction

A standard form will be developed to extract data from the included studies. From each article, the author, study design, study population, publication year, journal, participant demographics, OC used, intervention details, comparison groups, sleep outcomes, and the association between OC use and sleep will be extracted. Additionally, any mean values, standard deviation and confidence intervals, and all information needed for appraisal of internal validity

BMJ Open

will be extracted. This will be done in a standardized data extraction form by two reviewers independently. When consensus is not reached, a third researcher will be consulted to reach the final decision. Data will be presented in narrative form and summary tables.

Risk of bias assessment

For randomised controlled trials, the risk of bias in each included study for each outcome will be evaluated independently by two reviewers, using the Cochrane Collaboration Risk of Bias in randomised trials (RoB 2.0 tool).³⁶ Studies will be assessed from 5 domains: bias from randomisation, bias from deviates from intended interventions, bias due to missing data, bias in outcome measurement and bias in the selection of the reported result. ³⁶ An overall rating of low bias, some concerns about bias or high bias will be given depending on the result of assessment. The Cochrane Risk of Bias in Non-randomised studies – of Interventions (ROBINS-1 tool) will be used to assess the risk of bias for each outcome in non-randomised comparative studies. ³⁷ Risk of Bias in Systematic Reviews (ROBIS) tool will be used to assess the risk of bias for the eligible systematic reviews.³⁸

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Grading the strength of evidence

The certainty of the evidence per outcome for each comparison will be assessed from five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach and be classified into four levels of evidence (high, moderate, low or very low).³⁹

Data synthesis

All data extracted will be presented in both narrative form and in summary tables. If data is missing, the study authors will be contacted to try to obtain the data. For sleep measures investigated by three or more studies, heterogeneity will be assessed using Q statistic with a p

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

value < 0.1 indicating for significant heterogeneity. The I² statistic will also be calculated with 25%, 50% and 75% representing low, medium, and high heterogeneity, respectively.⁴⁰ The heterogeneity in OC effects may be caused by differences in study populations (such as age of patients), different OC or doses received, length of follow-up, and other factors. If heterogeneity level is low or medium, we will conduct random-effects meta-analyses to estimate the magnitude of the overall effect of OC, with 95% confidence interval depicting the uncertainty around the estimate. Subgroup analyses (e.g., by age) and sensitivity analyses (e.g., by progesterone dose) will be conducted as if sufficient data are available.

DISCUSSION

Strengths and limitations

This systematic review will be the first to provide quantitative estimates of the association between OC use and sleep outcomes in healthy women. Our systematic review methodology includes explicit eligibility criteria created in consultation with research librarians, and the usage of tested, standardized abstraction forms. We will calibrate our review methods throughout the review process for optimal consistency among reviewers. The GRADE approach will be applied to aggregate data, the PRISMA-P reporting checklist is followed to draft this systematic review protocol, and the PRISMA reporting checklist will be followed to draft this systematic review later. The κ statistic will be reported to identify issues with reproducibility. Our review will encompass a wide range of OC formulations and sleep outcome measurements. We anticipate limitations with regard to publication bias and recall bias as the majority of studies employ selfadministered tools to assess sleep quality and duration.

Study implications

BMJ Open

Sleep quality is a crucial outcome that affect overall life quality in women of reproductive age and may indicate risk of developing comorbid conditions. The relationship between OC use and sleep quality, duration and disorder have been reported inconsistently in the current literature. OC have been more and more widely accepted by women. However, no study has attempted to provide systematic evidence on the association between OC use and sleep. Our systematic review will elucidate the association between OC use and sleep quality. Moreover, it will contribute evidence that will support the improvement of guidelines for taking OC in healthy women and promote awareness of safety for taking OC.

It is challenging to design, conduct, and analyze original studies investigating the association between OC use and sleep quality. For instance, a wide variety of OC are utilized in women and they may change to other brands of OC tablets or birth control methods. In addition, most studies use subjective sleep measures, which may involve recall the information in the past. Through appraisal of published studies, our systematic review will inform the improvement in the design and implementation of future research in this field.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Conflict of Interest Disclosures: All the authors have declared no financial conflicts of interest. **Funding:** Dr. Chunxue Wang and Dr. Ning Zhang are supported by the National Key Research & Development Program of China [grant number 2016YFC1307200], and Beijing Key Clinical Specialty Construction Project.

Author Contributions: JM, MC, CW, and XY conceptualized the idea of the study. JM, XY and MC drafted the manuscript. CW, LT, CM, NZ, QW critically appraised the methodology. All authors contributed to and approve of the final version of the manuscript.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Table 1: Search Strategies for OVID Medline, Embase and Cochrane Central

Database(s): OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present

1 exp contraceptive agents/ or exp hormonal contraception/ 2 exp contraception/ or fertility control.mp. or fertilization inhibition.mp. or inhibition of fertilization.mp. 3 exp birth control/ 4 exp family planning services/ 5 desogestrel/ or norpregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 no	#	Searches
2 exp contraception/ or fertility control.mp. or fertilization inhibition.mp. or inhibition of fertilization.mp. 3 exp birth control/ 4 exp family planning services/ 5 desogestrel/ or norpregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 20 norgestrel.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. <td>1</td> <td>exp contraceptive agents/ or exp hormonal contraception/</td>	1	exp contraceptive agents/ or exp hormonal contraception/
ifertilization.mp. 3 exp birth control/ 4 exp family planning services/ 5 desogestrel/ or norpregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestin\$mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	2	exp contraception/ or fertility control.mp. or fertilization inhibition.mp. or inhibition of
3 exp birth control/ 4 exp family planning services/ 5 desogestrel/ or norpregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestin\$mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.		fertilization.mp.
4 exp family planning services/ 5 desogestrel/ or norpregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	3	exp birth control/
5 desogestrel/ or norpregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	4	exp family planning services/
6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	5	desogestrel/ or norpregnenes/ or progesterone congeners/
7 dienogest.mp. 8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	6	exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp.
8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	7	dienogest.mp.
9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	8	exp progestin/ or progestin\$.mp. or progestogen.mp.
10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	9	lynestrenol/
11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	10	norethindrone/
12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	11	levonorgestrel/
13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	12	(etynodiol diacetate or ethynodiol diacetate).mp.
14mestranol.mp. or exp mestranol/15exp estradiol/ or estradiol.mp. or oetradiol.mp.16(desogestrel or norpregnene\$ or progestins).mp.17(progesterone congeners adj2 synthetic).mp.18drospirenone.mp.19lynestrenol.mp.20norethindrone.mp.21norgestrel.mp.22etonogestrel.mp.23gestodene.mp.24(levonorgestrel or D-norgestrel).mp.25norgestimate.mp.26dienogest.mp.	13	norgestrel/
15exp estradiol/ or estradiol.mp. or oetradiol.mp.16(desogestrel or norpregnene\$ or progestins).mp.17(progesterone congeners adj2 synthetic).mp.18drospirenone.mp.19lynestrenol.mp.20norethindrone.mp.21norgestrel.mp.22etonogestrel.mp.23gestodene.mp.24(levonorgestrel or D-norgestrel).mp.25norgestimate.mp.26dienogest.mp.	14	mestranol.mp. or exp mestranol/
16(desogestrel or norpregnene\$ or progestins).mp.17(progesterone congeners adj2 synthetic).mp.18drospirenone.mp.19lynestrenol.mp.20norethindrone.mp.21norgestrel.mp.22etonogestrel.mp.23gestodene.mp.24(levonorgestrel or D-norgestrel).mp.25norgestimate.mp.26dienogest.mp.	15	exp estradiol/ or estradiol.mp. or oetradiol.mp.
17(progesterone congeners adj2 synthetic).mp.18drospirenone.mp.19lynestrenol.mp.20norethindrone.mp.21norgestrel.mp.22etonogestrel.mp.23gestodene.mp.24(levonorgestrel or D-norgestrel).mp.25norgestimate.mp.26dienogest.mp.	16	(desogestrel or norpregnene\$ or progestins).mp.
18drospirenone.mp.19lynestrenol.mp.20norethindrone.mp.21norgestrel.mp.22etonogestrel.mp.23gestodene.mp.24(levonorgestrel or D-norgestrel).mp.25norgestimate.mp.26dienogest.mp.	17	(progesterone congeners adj2 synthetic).mp.
19lynestrenol.mp.20norethindrone.mp.21norgestrel.mp.22etonogestrel.mp.23gestodene.mp.24(levonorgestrel or D-norgestrel).mp.25norgestimate.mp.26dienogest.mp.	18	drospirenone.mp.
20norethindrone.mp.21norgestrel.mp.22etonogestrel.mp.23gestodene.mp.24(levonorgestrel or D-norgestrel).mp.25norgestimate.mp.26dienogest.mp.	19	lynestrenol.mp.
21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	20	norethindrone.mp.
22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	21	norgestrel.mp.
23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	22	etonogestrel.mp.
24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp.	23	gestodene.mp.
25 norgestimate.mp. 26 dienogest.mp.	24	(levonorgestrel or D-norgestrel).mp.
26 dienogest.mp.	25	norgestimate.mp.
	26	dienogest.mp.
27 contracept*.mp.	27	contracept*.mp.
28 birth control.mp.	28	birth control.mp.
29 family planning.mp.	29	family planning.mp.
30 or/1-29	30	or/1-29
31 exp sleep/	31	exp sleep/

32	exp sleep-wake transition disorders/ or exp sleep deprivation/ or exp sleep wake
	disorders/ or exp dyssomnias/
33	(fragmented sleep or insufficient sleep syndrome\$).mp.
34	exp sleep latency/ or exp sleep hygiene/
35	exp sleep arousal disorder/
36	exp sleep disorder/
37	sleep.mp.
38	(insomnia\$ or hypersomnia\$).mp. or "disorders of excessive somnolence"/
39	exp restless legs syndrome/ or restless legs syndrome.mp.
40	or/31-39
41	(comment or letter or editorial or note or erratum or short survey or news or newspaper
	article or patient education handout or case reports or historical article).pt.
42	animal/ not human/
43	or/41-42
44	(30 and 40) not 43
45	limit 44 to yr="1970-current"

Database: Embase 1974 to 2020 August 17

#	Searches
1	exp contraceptive agents/ or hormonal contraception/
2	exp contraception/ or fertility control.mp. or fertilization inhibition.mp. or inhibition of fertilization.mp.
3	exp birth control/
4	exp family planning services/
5	desogestrel/ or norpregnenes/ or progesterone congeners/
6	exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp.
7	dienogest.mp.
8	exp progestin/ or progestin\$.mp. or progestogen.mp.
9	lynestrenol/
10	norethindrone/
11	norgestrel/
12	levonorgestrel/
13	(etynodiol diacetate or ethynodiol diacetate).mp.
14	mestranol.mp. or exp mestranol/
15	exp estradiol/ or estradiol.mp. or oetradiol.mp.
16	(desogestrel or norpregnene\$ or progestins).mp.
17	(progesterone congeners adj2 synthetic).mp.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2	
2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
11	
12	
13	
14	
15	
16	
10	
17	
18	
19	
20	
20	
21	
22	
23	
24	
24	
25	
26	
27	
28	
20	
29	
30	
31	
22	
22	
33	
34	
35	
36	
20	
37	
38	
39	
40	
_TU	
41	
42	
43	
44	
15	
45	
46	
47	
48	
10	
49	
50	
51	
52	
52	
55	
54	
55	
56	
57	
57	
58	
FO	
59	

1

18	drospirenone.mp.
19	lynestrenol.mp.
20	norethindrone.mp.
21	norgestrel.mp.
22	etonogestrel.mp.
23	gestodene.mp.
24	(levonorgestrel or D-norgestrel).mp.
25	norgestimate.mp.
26	dienogest.mp.
27	contracept*.mp.
28	Birth Control.mp.
29	Family planning.mp.
30	or/1-29
31	exp sleep/
32	exp Sleep-Wake Transition Disorders/ or exp Sleep Deprivation/ or exp Sleep Wake
	Disorders/ or exp dyssomnias/
33	(fragmented sleep or insufficient sleep syndrome\$).mp.
34	exp sleep latency/ or exp sleep hygiene/
35	exp sleep arousal disorder/
36	sleep*.mp.
37	(insomnia\$ or hypersomnia\$).mp. or "disorders of excessive somnolence"/
38	exp restless legs syndrome/ or restless legs syndrome.mp.
39	exp sleep disorder/
40	or/31-39
41	(editorial or note or letter erratum or short survey or abstract).pt. or abstract report/ or
	letter/ or case study/
42	animal/ not human/
43	or/41-42
44	exp female/ or female\$.mp. or women.mp. or woman.mp.
45	(30 and 40 and 44) not 43
46	limit 45 to yr="1970-current"

Database: Cochrane Central

#	Searches
1	MeSH descriptor: [Contraceptive Agents] explode all trees
2	MeSH descriptor: [Hormonal Contraception] explode all trees

3	MeSH descriptor: [Contraception] explode all trees
4	Fertility Control
5	Fertilization inhibition
6	inhibition of fertilization
7	MeSH descriptor: [Family Planning Services] explode all trees
8	MeSH descriptor: [Desogestrel] this term only
9	MeSH descriptor: [Norpregnenes] this term only
10	MeSH descriptor: [Progesterone Congeners] this term only
11	MeSH descriptor: [Ethinyl Estradiol] explode all trees
12	ethinyl estradiol
13	ethinylestradiol
14	dienogest
15	MeSH descriptor: [Progestins] explode all trees
16	progestin\$
17	progestogen
18	MeSH descriptor: [Lynestrenol] this term only
19	MeSH descriptor: [Norethindrone] this term only
20	MeSH descriptor: [Norgestrel] this term only
21	MeSH descriptor: [Levonorgestrel] this term only
22	(Etynodiol diacetate) OR (Ethyndiol diacetate)
23	mestranol
24	MeSH descriptor: [Mestranol] explode all trees
25	MeSH descriptor: [Estradiol] explode all trees
26	estradiol
27	oetradiol
28	(desogestrel or norpregnene\$ or progestins)
29	progesterone congeners adj2 synthetic
30	drospirenone
31	lynestrenol
32	norethindrone
33	norgestrel
34	etonogestrel
35	gestodene
36	levonorgestrel or d-norgestrel
37	norgestimate
38	dienogest
39	contracept*
40	birth control
41	family planning
42	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 o
	18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or
	33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41
12	MeSH descriptor: [Sleen] explode all trees

BM

Protected by copyright, including for uses related to text and data mining. Al training, and similar technologies.	Enseignement Superieur (ABES) .	Dpen: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographiq
--	---------------------------------	--

44	MeSH descriptor: [Sleep-Wake Transition Disorders] explode all trees
45	MeSH descriptor: [Sleep Deprivation] explode all trees
46	MeSH descriptor: [Sleep Wake Disorders] explode all trees
47	MeSH descriptor: [Dyssomnias] explode all trees
48	fragmented sleep or insufficient sleep syndrome\$
49	MeSH descriptor: [Sleep Hygiene] explode all trees
50	MeSH descriptor: [Sleep Latency] explode all trees
51	MeSH descriptor: [Sleep Arousal Disorders] explode all trees
52	sleep*
53	insomnia\$ or hypersomnia\$
54	disorders of excessive somnolence
55	MeSH descriptor: [Restless Legs Syndrome] explode all trees
56	restless legs syndrome
57	43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56
58	(comment or letter or editorial or note or erratum or short survey or news or newspaper
	article or patient education handout or case reports or historical article).pt.
59	MeSH descriptor: [Animals] explode all trees
60	MeSH descriptor: [Humans] explode all trees
61	58 and 59 not 60
62	(42 and 57) not 61
63	limit 62 to yr="1970-current"
REFI	

REFERENCES

- 1. United Nations. Contraceptive Use by Method 2019: Data Booklet [Internet]. UN; 2019 [cited 2020 Jul 20]. Available from: https://www.un-ilibrary.org/population-anddemography/contraceptive-use-by-method-2019 1bd58a10-en
- 2. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. [Internet]. 2013 Sep 12 [cited 2020 Jul 20]; 347(sep12 1):f5298-f5298. Available from: https://pubmed.ncbi.nlm.nih.gov/24030561/
- 3. Dhont M. History of oral contraception. Eur J Contracept Reprod Health Care [Internet]. 2010 Dec [cited 2020 Jul 20];15 Suppl 2:S12-18. Available from: https://pubmed.ncbi.nlm.nih.gov/21091163/

BMJ Open

4.	LeBlanc ES, Laws A. Benefits and Risks of Third-Generation Oral Contraceptives. J Gen
	Intern Med [Internet]. 1999 Oct [cited 2020 Jul 20];14(10):625-32. Available from:
	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1496751/
5.	Davtyan C. Four Generations of Progestins in Oral Contraceptives. Proceedings of
	UCLA Healthcare [Internet]. 2012 [cited 15 May 2020];16. Available from:
	https://proceedings.med.ucla.edu/index.php/2012/09/12/four-generations-of-progestins-in
	-oral-contraceptives/
5.	Lancel M, Faulhaber J, Schiffelholz T, Romeo E, Di Michele F, Holsboer F, et al.
	Allopregnanolone affects sleep in a benzodiazepine-like fashion. J Pharmacol Exp Ther
	[Internet]. 1997 Sep [cited 2020 Jul 20] ;282(3):1213-8. Available from:
	https://pubmed.ncbi.nlm.nih.gov/9316828/
7.	Allada R, Cirelli C, Sehgal A. Molecular Mechanisms of Sleep Homeostasis in Flies and
	Mammals. Cold Spring Harb Perspect Biol [Internet]. 2017 Aug 1[cited 2020 Jul
	20];9(8). Available from:
	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538413/Schwartz MD, Mong JA.
8.	Estradiol modulates recovery of REM sleep in a time-of-day-dependent manner.
	American Journal of Physiology-Regulatory, Integrative and Comparative Physiology.
	2013 May 15;305(3):R271–80.
).	Bezerra AG, Andersen ML, Pires GN, Tufik S, Hachul H. Effects of hormonal
	contraceptives on sleep - A possible treatment for insomnia in premenopausal women.
	Sleep Sci [Internet]. 2018 Jun [cited 2020 Jul 20];11(3):129–36. Available from:
	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201525/
10	. Léger D, Bayon V. Societal costs of insomnia. Sleep Med Rev. 2010;14(6):379-89.
11	. Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16(5):873-97; discussion
	854.
12	. Gourineni R. Prognosis and complications. In: Attarian HP, ed. Clinical Handbook of
	Insomnia. 3rd ed. New York: Springer; 2017. p. 59-73.
13	. Kessler, R.C., Berglund, P.A., Coulouvrat, C., Hajak, G., Roth, T., Shahly, V., et al.
	(2011). Insomnia and the performance of US workers: results from the America insomnia
	<u>survey</u> . <i>Sleep</i> ; 34(9): 1161–1171.
	20

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Research International; 2016: 1764837. https://pubmed.ncbi.nlm.nih.gov/10561657/ https://pubmed.ncbi.nlm.nih.gov/24014598/ https://pubmed.ncbi.nlm.nih.gov/9198174/ https://pubmed.ncbi.nlm.nih.gov/28188769/ https://pubmed.ncbi.nlm.nih.gov/28612347/

- 14. Ohayon, M.M., O'Hara, R., Vitiello, M.V. (2012). Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Medicine Reviews: 16(4): 283–295.
- 15. Wimms, A., Woehrle, H., Ketheeswaran, S., Ramanan, D., Armitstead, J. (2016). Obstructive Sleep Apnea in Women: Specific Issues and Interventions. Biomed
- 16. Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2020 Sep 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK279054/
- 17. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol [Internet]. 1999 Nov [cited 2020 Jul 20] ;181(5 Pt 1):1263–9. Available from:
- 18. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review. Cancer Epidemiol Biomarkers Prev [Internet]. 2013 Nov 1 [cited 2020 Jul 20];22(11):1931–43. Available from:
- 19. Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost [Internet]. 1997 Jul [cited 2020 Jul 20] ;78(1):327–33. Available from:
- 20. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: The Royal College of General Practitioners' Oral Contraception Study. American Journal of Obstetrics and Gynecology [Internet]. 2017 Jun 1 [cited 2020 Jul 20] ;216(6):580.e1-580.e9. Available from:
- 21. Liu H, Yao J, Wang W, Zhang D. Association between duration of oral contraceptive use and risk of hypertension: A meta-analysis. J Clin Hypertens (Greenwich) [Internet]. 2017 Oct [cited 2020 Jul 20];19(10):1032–41. Available from:

BMJ Open

22.	Guida M, Rega A, Vivone I, Saccone G, Sarno L, Di Carlo C, et al. Variations in sleep
	associated with different types of hormonal contraceptives. Gynecol Endocrinol
	[Internet]. 2020 Feb [cited 2020 Jul 20] ;36(2):166–70. Available from:
	https://pubmed.ncbi.nlm.nih.gov/31311352/
23.	Hachul H, Andersen ML, Bittencourt L, Santos-Silva R, Tufik S. A population-based
	survey on the influence of the menstrual cycle and the use of hormonal contraceptives on
	sleep patterns in São Paulo, Brazil. Int J Gynaecol Obstet [Internet]. 2013 Feb[cited 2020
	Jul 20];120(2):137–40. Available from:
	https://www.sciencedirect.com/science/article/abs/pii/S0020729212005619
4.	Lundin C, Danielsson KG, Bixo M, Moby L, Bengtsdotter H, Jawad I, et al. Combined
	oral contraceptive use is associated with both improvement and worsening of mood in the
	different phases of the treatment cycle-A double-blind, placebo-controlled randomized
	trial. Psychoneuroendocrinology [Internet]. 2017[cited 2020 Jul 20];76:135-43.
	Available from: https://pubmed.ncbi.nlm.nih.gov/27923181/
5.	Bezerra AG, Andersen ML, Pires GN, Banzoli CV, Polesel DN, Tufik S, et al. Hormonal
	contraceptive use and subjective sleep reports in women: An online survey. J Sleep Res
	[Internet]. 2020 Jan 27 [cited 2020 Jul 20] ;e12983. Available from:
	https://pubmed.ncbi.nlm.nih.gov/31989746/
6.	Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., &
	Stewart, L. A. (2015). Preferred reporting items for systematic review and meta-analysis
	protocols (PRISMA-P) 2015 statement. Systematic reviews, 4(1), 1.
27.	Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A
	new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol.
	2016;69:225-34.
28.	Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-
	2010, and changes in patterns of use since 1995. Natl Health Stat Report [Internet].2012
	Oct 18;(60):1–25.Available from:
	https://pubmed.ncbi.nlm.nih.gov/24988814/#:~:text=Use%20of%20intrauterine%20devic
	es%20as current%20%20most%20effective%20contracentive%20method

- 29. Rao U, Hammen CL, Poland RE. Ethnic differences in electroencephalographic sleep patterns in adolescents. Asian J Psychiatr [Internet]. 2009 Mar 1;2(1):17–24. Available from: <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786078/</u>
 - 30. Grandner MA, Patel NP, Gehrman PR, Xie D, Sha D, Weaver T, et al. Who Gets the Best Sleep? Ethnic and Socioeconomic Factors Related to Sleep Complaints. Sleep Med [Internet]. 2010 May;11(5):470–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861987/
 - 31. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res [Internet]. 1989 May [cited 2020 Jul 20] ;28(2):193–213. Available from: https://pubmed.ncbi.nlm.nih.gov/2748771/
 - 32. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep [Internet]. 1991 Dec [cited 2020 Jul 20];14(6):540–5. Available from: https://pubmed.ncbi.nlm.nih.gov/1798888/
 - Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. Journal of Psychosomatic Research [Internet].
 2000[cited 2020 July 20] ;48:555–60. Available from: https://pubmed.ncbi.nlm.nih.gov/11033374/
 - 34. The Insomnia Severity Index: Psychometric Indicators to Detect Insomnia Cases and Evaluate Treatment Response [Internet]. [cited 2020 Jul 20]. Available from: <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079939/</u>
 - 35. Kanarkowski R, Tornatore KM, D'Ambrosio R, Gardner MJ, Jusko WJ. Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clinical Pharmacology & Therapeutics. 1988;43(1):23–31.
 - 36. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 Aug 28 [cited 2020 Sep 28];366. Available from: <u>https://www.bmj.com/content/366/bmj.14898</u>
 - 37. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 [cited 2020 Jul 20]; 28;366:14898. Available from: <u>https://pubmed.ncbi.nlm.nih.gov/31462531/</u>

- BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text ining, Al training, and similar technologies
- 38. Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225-34.
- 39. Schünemann HJ, Brożek J, Guyatt G, Oxman A. GRADE handbook [Internet]. GRADE Handbook. 2013 [cited 2020 Sep 28]. Available from: <u>https://gdt.gradepro.org/app/handbook/handbook.html</u>
- 40. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-J. 2003 Sep 4,... analyses. BMJ. 2003 Sep 4;327(7414):557-60.

Reporting checklist for protocol of a systematic review.

Instructions to authors

Based on the PRISMA-P guidelines.						
Instructions	to auth	iors				
Complete this checklist by entering the page numbers from your manuscript where readers will find each of titems listed below.						
Your article may r missing information explanation.	not currer on. If you	ntly address all the items on the checklist. Please modify your text to a are certain that an item does not apply, please write "n/a" and provi	include the ide a short			
Upload your comp	pleted che	ecklist as an extra file when you submit to a journal.				
In your methods s	ection, sa	y that you used the PRISMA-Preporting guidelines, and cite them a	s:			
Moher D, Shamse Reporting Items fo 2015;4(1):1.	eer L, Clai or System	rke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. I natic Review and Meta-Analysis Protocols (PRISMA-P) 2015 staten	Preferred nent. Syst Rev.			
		Ponorting Itom				
		Reporting item	Page Number			
Title			Page Number			
Title Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	Page Number			
Title Identification Update	<u>#1a</u> <u>#1b</u>	Identify the report as a protocol of a systematic review If the protocol is for an update of a previous systematic review, identify as such	Page Number 1 n/a-not an update			
Title Identification Update Registration	<u>#1a</u> <u>#1b</u>	Identify the report as a protocol of a systematic review If the protocol is for an update of a previous systematic review, identify as such	Page Number 1 n/a-not an update			
Title Identification Update Registration	<u>#1a</u> <u>#1b</u> <u>#2</u>	Identify the report as a protocol of a systematic review If the protocol is for an update of a previous systematic review, identify as such If registered, provide the name of the registry (such as PROSPERO) and registration number	Page Number 1 n/a-not an update 2-PROSPERO pending			
Title Identification Update Registration Authors	<u>#1a</u> <u>#1b</u> <u>#2</u>	Identify the report as a protocol of a systematic review If the protocol is for an update of a previous systematic review, identify as such If registered, provide the name of the registry (such as PROSPERO) and registration number	Page Number 1 n/a-not an update 2-PROSPERO pending			
Title Identification Update Registration Authors Contact	#1a #1b #2 #3a	Identify the report as a protocol of a systematic review If the protocol is for an update of a previous systematic review, identify as such If registered, provide the name of the registry (such as PROSPERO) and registration number Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	Page Number 1 n/a-not an update 2-PROSPERO pending 1			

	<u>#4</u>	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/
Support			
Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	1
Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	n/
Role of sponsor or funder	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	n/
Introduction			
Rationale	<u>#6</u>	Describe the rationale for the review in the context of what is already known	4-
Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	
Methods			
Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	8-1
Information sources	<u>#9</u>	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	
Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	15-1
Study records - data management	<u>#11a</u>	Describe the mechanism(s) that will be used to manage records and data throughout the review	1
Study records - selection process	<u>#11b</u>	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	
	⊢or p	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Study records -	<u>#11c</u>	Describe planned method of extracting data from reports (such as	8
data collection process		piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	
Data items	<u>#12</u>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	11
Outcomes and prioritization	<u>#13</u>	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	9-11cted by cop
Risk of bias in individual studie	<u>#14</u> s	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	yright, including foi 12
Data synthesis	<u>#15a</u>	Describe criteria under which study data will be quantitatively synthesised	12es relat
Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall's τ)	12-13 to text and data
Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	13 13 g, Al
Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the type of summary planned	12-13 inng, a
Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	
Confidence in cumulative evidence	<u>#17</u>	Describe how the strength of the body of evidence will be assessed (such as GRADE)	12nnologies.
Notes:			
• 1b: n/a-not	an update		
• 2: 2-PROSE Commons A https://www	PERO pendi Attribution I	ng The PRISMA-P checklist is distributed under the terms of the Creative License CC-BY 4.0. This checklist was completed on 07. October 2020 usin ts.org/, a tool made by the <u>EQUATOR Network</u> in collaboration with <u>Penel</u>	g ope.ai

BMJ Open

The Relationship between Hormonal Contraceptives and Insomnia among Women of Reproductive Age: A Systematic Review Protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-045819.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Mar-2021
Complete List of Authors:	Ma, Jinhui; McMaster University, Department of Health Research Methods, Evidence, and Impact Cheng, Megan; McMaster University Faculty of Health Sciences, Thabane, Lehana; McMaster University, Department of Health Research Methodology, Evidence, and Impact Ma, Caihong; Peking University Third Hospital, Zhang, Ning; Beijing Tiantan Hospital, Capital Medical University, Department of Neuropsychiatry and Behavioral Neurology ; Capital Medical University, Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Wang, Qi; McMaster University, Department of Health Research Methods, Evidence, and Impact Kim, Hyunwoo; McMaster University, Department of Health Research Methods, Evidence, and Impact Reza, Hameed; McMaster University, Faculty of Science Wang, Chunxue; Beijing Tiantan Hospital, Capital Medical University; Capital Medical University, 5Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Wang, Chunxue; Beijing Tiantan Hospital, Capital Medical University; Capital Medical University, 5Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Yao, Xiaomei; McMaster University, Department of Health Research Methods, Evidence and Impact; McMaster University, Department of Methods, Evidence and Impact; McMaster University, Department of Oncology
Primary Subject Heading :	Reproductive medicine
Secondary Subject Heading:	Public health
Keywords:	REPRODUCTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



The Relationship between Hormonal Contraceptives and Insomnia among Women of Reproductive Age: A Systematic Review Protocol

Jinhui Ma¹, Megan Cheng², Lehana Thabane¹, Caihong Ma³, Ning Zhang⁴, Qi Wang¹, Hyunwoo Kim¹, Hameed Reza⁵, Chunxue Wang⁴, Xiaomei Yao^{1,6}

¹Department of Health Research Methods, Evidence, and Impact, McMaster University,

Hamilton, Ontario, Canada

²Faculty of Health Science, McMaster University, Hamilton, Ontario, Canada

³Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking

University Third Hospital, Beijing, China

⁴Department of Neuropsychiatry and Behavioral Neurology, Beijing Tiantan Hospital, Capital

Medical University, Beijing, China

⁵Faculty of Science, McMaster University, Hamilton, Ontario, Canada

⁶Center for Clinical Practice Guideline Conduction and Evaluation, Children's Hospital of Fudan

University, Shanghai, China

Corresponding:

Xiaomei Yao: 711 Concession Street, Hamilton, L8V 1C3, ON, Canada, Tel: +1-9055274322

ext. 42824, E-mail: yaoxia@mcmaster.ca

Chunxue Wang: No. 119 South Fourth Ring West Road, Fengtai District, Beijing 100070, P.R.

China ,Tel: +01186-13701193710, E-mail: snowsen@126.com

ABSTRACT

Introduction The exact etiology of sleep disruptions is unknown but hormonal fluctuations during the menstrual cycle, pregnancy, and menopause have been shown to potentially affect how well a woman sleeps. The aim of this systematic review is to investigate whether oral contraceptives (OC) and other hormonal contraceptives are associated with a decreased quality of sleep and increased sleep duration in women of reproductive age.

Methods This review will analyze data from randomized controlled trials or non-randomized comparative studies investigating the association between hormonal contraceptives, especially OC (second generation or further), and sleep-related outcomes among women of reproductive age, including sleep quality and sleep disorders. Reviews addressing the same research question with similar inclusion/exclusion criteria will be included. A literature search will be performed using the MEDLINE, EMBASE and Cochrane CENTRAL databases. Risk of methodological bias will be assessed using The Cochrane Collaboration's revised tool for assessing risk of bias in randomised trials (RoB 2.0). Two reviewers will independently assess eligibility of studies, risk of bias and extract the data. A third author will solve discrepancies. All extracted data will be presented in summary tables and narrative form. For sleep measures investigated by two or more studies with low heterogeneity, we will conduct random-effects meta-analysis to estimate the magnitude of the overall effect of hormonal contraceptives. As long as studies included in the systematic review form a connected network, a network meta-analysis will be conducted to estimate the comparative effect of different contraceptives. The GRADE approach will be used to summarise the quality of evidence.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Keywords: hormonal contraceptive, oral contraceptive, contraception, sleep quality, sleep duration

Ethics and dissemination: Ethics approval is not required as we analyze data from previously reported studies.

PROSPERO registration number: CRD42020199958.

Article Summary

Strengths and Limitations of this study:

- This review on the association of oral contraceptive use and sleep is based on a robust, librarian consulted search strategy.
- All papers are assessed by two independent reviewers to mitigate bias.
- The quality of all papers will be assessed with the appropriate tool.
- Papers in languages other than English are not included, leading to potential for language bias.

Word Count: 3531

INTRODUCTION

The invention of oral contraceptives (OC) is a medical innovation which has evolved dramatically in the past decades.¹ The first-generation OC pill, Enovid, contained high doses of norethynodrel (i.e., progestin, 10 mg) and mestranol (i.e., estrogen, 150µg) and was introduced in 1960. To lower the risk of thromboembolic complications associated with the use of OC pills, the second-generation of OC was developed in the 1970s by lowering the dose of the progestin component from 10 mg to 1 mg, and the estrogen component from 150µg to 35µg. Development of new progestins, mainly levonorgestrel, gave way to the second generation of OCs, which contained a lower dosage of progesterone.² The second-generation OCs was shown to be associated with an increased risk of myocardial infarction, stroke, acne and weight gain, which were correlated with the androgenicity of the progestin.³ Subsequently, the third generation of OCs was developed in the 1990s to address side effects that arise due to the androgenicity of second generation progestins, such as acne and weight gain.³ Fourth generation OCs are more selective and bind specifically to the progesterone receptor, further reducing side effects such as edema and improving skin appearance.⁴ Presently, combined OCs containing both progesterone and estrogen, and progesterone only pills are used.

Worldwide, there are around 1.9 billion women of reproductive age. Hormonal contraceptives, OC, vaginal ring, contraceptive skin patches, implants, injections, and hormonal intrauterine contraceptive devices (IUDs), are widely used around the world in women of reproductive age.⁵ One hundred and fifty-one million women use OCs with usage varying by region.⁵ OC are used more widely in developed countries, especially Europe and North America, than in developing countries. ⁵ In 2019, 17.2% women of reproductive age in high-income countries, 6.7% in middle-income countries, and 3.8% in low-income countries used OC pills. ⁵
BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The prevalence of OC usage worldwide has remained stable in the last 25 years, however, the overall number of users increased since the world population has increased.⁵ Other hormonal contraceptives have been widely adopted as well and used by over 97 million women in the world.⁵ These hormonal contraceptives have different dosage, formulation, mechanism of action, and applicable groups compared to OCs.⁶ Unlike oral contraceptives which are taken consistently and provide a stable dosage of the estrogen and progestin components, other hormonal contraceptives have the potential to provide lower dose of progestin and estrogen. It has been shown that hormonal IUDs release levonorgestrel directly into the uterus, only a small amount is absorbed into the rest of the body, i.e. its effects are mostly paracrine rather then systemic. ⁷An investigation of Nexplanon, an implant contraceptive lasting 3 years, found progestin absorption at 60 mg/day after 3 months and 30mg/day after 6 months.⁸

Progesterone, the primary component in OCs and other hormonal contraceptives, is an agonist of gamma-aminobutyric acid (GABA) receptors through a metabolite allopregnanolone. ⁹ GABA is a crucial molecule in sleep promotion – most sleep-promoting neurons are sensitive to GABA. ¹⁰ Common sleep medications, such as benzodiazepines have been shown to positively modulate GABA signalling. ¹⁰ The potency of progestin is similar to that of benzodiazepines and has similar agonistic effects. Changes in electroencephalogram (EEG) activity seen with progesterone administration are similar to those evoked by benzodiazepines. ⁹ Studies in rat models have shown that administration of exogenous progesterone leads to dose-dependent decreased sleep latency and wakefulness. ⁹ The mechanism behind the effect of estrogen on sleep is not well elucidated but rat studies have shown that administration of estogen promotes sleep during the sleep period and reduces sleep during the wakefulness period.¹¹ The overall effect on sleep is likely

caused by a combination of both estrogen and progesterone, although the magnitude of their contribution to sleep changes is unknown.¹²

High quality sleep is as essential as regular exercise and eating a balanced diet for maintenance of optimal health and well-being. Severe sleeping problems, such as insomnia, are important matters from both a public health perspective and an individual level. Insomnia is associated with depression, anxiety, substance abuse, cognitive impairment, metabolic disorders (e.g., diabetes, dyslipidemia, and obesity) and cardiovascular diseases.¹³⁻¹⁵ Women are more likely than men to have sleep problems including insomnia and restless leg syndrome. The exact etiology of these sleep disruptions is unknown but hormonal fluctuations during the menstrual cycle, pregnancy, and menopause have been shown to potentially affect how well a woman sleeps.¹⁶⁻¹⁸ During ovulation, there is a surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which leads to a decrease in estrogen concentration and an increase in progesterone.¹⁹ During the luteal phase, progesterone concentrations increase and estrogen levels are high up to the mid-phase. Starting from the mid-luteal phase, both estrogen and progesterone levels decrease.¹⁹ Sleep disturbances are most commonly reported at the end of the luteal phase and early follicular phase.²⁰ OCs are taken each day for 21 days, providing a constant, exogenous source of estrogen and progesterone, preventing the release of FSH and LH and thus the production of a follicle or ovulation.²¹ Therefore, OC use may affect women's sleep-wake cycle and cause physiological changes that lead to sleep disturbance.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Unlike other commonly prescribed drugs, OC pills and other contraceptives are taken by healthy women for long periods of time. Safety trials have focussed largely on breast cancer and venous thromboembolism (VTE) risk. ²²⁻²³ Despite decreases in estrogen concentration with later OC generations, its use has been shown to be associated with an increased risk of developing breast

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

cancer and venous thromboembolism.³ A 2017 cohort study found OC intake was associated with a reduced risk of colorectal, endometrial and ovarian cancers and increased risk of cervical and breast cancer.²⁴ Another meta-analysis found a positive association between OC usage and risk of hypertension. ²⁵ Studies in women have varied findings on the association between OC use and sleep quality and duration. Differences in methodology, including the formulation of contraceptives taken, stratification of formulations, measurements of sleep, or the phase of the menstrual cycle of naturally cycling women used as comparison may explain the different findings between studies. For instance, a pilot study published in 2020 by Guida et al found significantly increased sleep duration for users of oral progestins, oral gestodene and 13.5 mg levonorgestrel intrauterine systems, compared with naturally cycling women (women not currently using any hormonal contraceptive), and decreased sleep latency and better sleep quality for users of depotadministered contraceptives. ²⁶ However, a polysomnography study published in 2012 by Hachul *et al* found decreased sleep latency in women using OC and no difference in overall sleep quality. ²⁷ A randomized control trial by Lundin *et al* found no significant sleep related results, while a cross sectional analysis by Bezerra et al found that hormonal contraceptive users had worse sleep quality compared with their naturally cycling counterparts. ²⁸⁻²⁹

Given the high prevalence of hormonal contraceptive use among women of reproductive age and the relationship between hormonal contraceptive use and sleep varying in both magnitude and direction in the current literature, there is an urgent need to provide women with accurate, evidence based information to inform their use of hormonal contraception.²⁶⁻²⁹ Hence, the objective of this systematic review is to compile and elucidate the association between hormonal contraceptive, especially OC, use and sleep (including the quality of sleep, sleep disorders, and duration of sleep). Our hypothesis is that OCs and other hormonal contraceptives are associated

BMJ Open

with a decreased quality of sleep and increased sleep duration in women of reproductive age. Findings from this review will provide insights to women choosing between different methods and formulations, while also inform the development of new progestins for future generations of OCs. The systematic review protocol was registered at the website of the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD42020199958).

METHODS

Our protocol follows the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015) guidelines.³⁰

Patient and Public Involvement

No patients were involved in this protocol.

Literature search

We developed a comprehensive search strategy with input from a research librarian at McMaster University. The systematic search for existing relevant systematic review and original studies is conducted in the Ovid MEDLINE and Embase (Excerpta Medica dataBASE) electronic databases, and the Cochrane Library (including Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials). Search terms covered all words related to birth control, ingredients of oral contraceptives, hormonal contraceptives, menstrual cycle, and sleep. We limited the search to studies or systematic reviews published from 1970 to present to ensure that we include all published studies or reviewers on second and further generation OCs. For sleep outcome measures, we searched sleep terms in the full text besides the title and abstract in case sleep is investigated as a secondary outcome and therefore not reported in the abstract. The BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

and data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text

comprehensive search strategies for each database are presented in Table 1. The reference lists of all included studies will be checked to identify additional potentially eligible studies.

Study Selection and Screening

Systematic screening of the studies will be first conducted at the title and abstract level, and then at the full-text level to determine if a study meets eligibility criteria by two independent reviewers. Any potential conflicts between the reviewers will be resolved through discussion. If discrepancies in judgment remain after discussion, a third-party reviewer will be consulted to resolve the conflict and provide a final decision.

Eligibility criteria

(1) Study Characteristics

Existing systematic reviews will be included if they (i) address the same research question with similar inclusion and exclusion criteria as ours; and (ii) have a low risk of bias in study eligibility criteria, identification and selection of studies, data collection and study appraisal, and synthesis and findings assessed using the Risk of Bias in Systematic Reviews (ROBIS) tool.³¹

For original studies, we will include (i) randomized controlled trials and non-randomized comparative studies that take into account the effect of potential confounders (e.g., age, race, and socioeconomic status)³²⁻³⁴ using methods such as multivariable analysis, propensity-score matching, or showing no statistically significant differences in baseline characteristics between participants in comparison groups; (ii) studies on human participants; (iii) studies investigate second generation or more recent OCs; and (iv) studies investigate the association between OC use and sleep-related outcomes, either as the primary or secondary objective.

(2) Participants

Participants or subgroups of participants are females between 15 and 49 years old.

BMJ Open

(3) Exposure

Participants or subgroups of participants take second generation or more recent OC or other hormonal contraceptives containing both progesterone and estrogen or progesterone only, regardless of its brand, dose, and frequency, to avoid pregnancy, as long as their hormonal contraceptive use pattern is sustained for at least three months.

(4) Comparator

Included studies must have comparison groups of women who are using (i) non-hormonal contraceptives; (ii) naturally cycling (i.e., not use any contraceptive methods); (iii) same agent as the exposure but in different dose, frequency, and duration; and (iv) second generation or more recent OC or other contraceptives but different from the exposure. Since recent usage or cessation of hormonal contraceptive use may cause hormonal oscillations, we will only include studies with participants keeping their contraceptive use pattern (either using or not using hormonal contraceptives) for at least three months.

(5) Outcomes

We are interested in any sleep-related outcomes and a variety of sleep measurements for sleep quality, sleep duration, and sleep disorder will be included in this systematic review. The sleep measurements can be questionnaires based on Likert Scale items listed below but not limited to these tools:

(i) The Pittsburgh Sleep Quality Index (PSQI). ³⁵ It measures seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction over the last four weeks. The PSQI is a subjective measure of sleep. Subjects self-rate each of the seven domains of sleep from 0 to 3, where 3 represents the negative extreme on the Likert

Scale. A subject with a global sum of 5 or greater is considered as a poor sleeper. Studies reported sleep quality in any of the above seven domains during and after taking OCs will be included in the review.

- (ii) The Epworth Sleepiness Scale (ESS) is a self-administered test used to assess daytime sleepiness.³⁶ It consists of 8 questions with different scenarios and a scale from 0-3 where subjects would indicate how likely they are to fall asleep in that situation. The scores are summed for a total score between 0 and 24. ³⁶ Studies reporting sleepiness with any of the 8 questions during and after taking OCs will be included in the review.
- (iii) The Athens Insomnia Scale (AIS), which is also a self-administered psychometric instrument designed for quantifying sleep difficulty.³⁷ The AIS consists of eight items: sleep induction (i.e., time to fall asleep after turning-off the lights), night awakenings, final awakening earlier than desired, total sleep duration, overall quality of sleep, sense of well-being during the day, functioning (physical and mental) during the day, and sleepiness during the day. Each item is rated from 0 to 3 with higher scores indicating more impaired sleep. The total score ranges from 0 to 24 and a total score of 6 or more is considered as insomnia. Studies reported any or all of the above eight insomniarelated items during and after taking OCs will be included in the review.
- (iv) The Insomnia Severity Index (ISI), a self-administered questionnaire used to assess insomnia. ³⁸ The ISI consists has a one month recall period and assesses 7 domains: severity of sleep onset, sleep maintenance, difficultly waking up in the morning, sleep dissatisfaction, interference of sleep with daytime functioning, noticeability of sleep problems by others, and distress caused by sleep difficulties. Each domain is rated on a scale from 0 to 4 with higher scores indicating more problematic sleep. The score is

BMJ Open

summed forming a total score between 0 and 28, with a score of 8 and above indicative of insomnia. ³⁸ Studies reporting any domains from the ISI during and after taking OCs will be included in the review.

We will also include continuous measures of sleep quality and disorder. These measures include: (i) total amount of sleep obtained, either during nocturnal sleep episode or across the 24-hour period; (ii) sleep latency, i.e., how long it takes the participant to fall asleep; (iii) how many times the participant wakes up; (iv) how many minutes the participant is awake during the night; (v) sleep efficiency, i.e., what percentage of time spent in bed is the participant actually asleep. The total sleep time is equal to the total amount of time spent in bed (in minutes) minus the sum of time it takes to fall asleep and the time spent awake throughout the night. The percentage is calculated as the total sleep time divided by total time in bed. Given we will only include studies with participants keeping their contraceptive use pattern for at least three months, the sleep outcomes from the eligible studies will be summarized after participants keeping their contraceptive use pattern for at least three months as well.

Exclusion criteria

The following studies will be excluded from this systematic review: (1) studies only recruited patients with specific comorbidities or conditions, such as hormonal disorder, acne, perimenopause, postmenopause, dysmenorrhea, depression etc., since these conditions may be associated with sleep problems and will not allow us to elucidate the association between hormonal contraceptives and sleep; (2) studies investigating the first-generation OC since it is not available in the market anymore due to severe side effects; (3) studies investigating emergency contraception; and (4) studies in languages other than English. We will exclude emergency

contraception from this review as the hormonal effect of the contraception is significantly different from long-acting contraception. The half-life of oral leovnoregestrel is around 24-32 hours, which is not significant when considering long-term effect on sleep.³⁹

Data abstraction

A standard form will be developed to extract data from the included studies. From each article, the author, study design, study population, publication year, journal, participant demographics, OC used, intervention details, comparison groups, sleep outcomes, and the association between OC use and sleep will be extracted. Additionally, any mean values, standard deviation and confidence intervals, and all information needed for appraisal of internal validity will be extracted. This will be done in a standardized data extraction form by two reviewers independently. When consensus is not reached, a third researcher will be consulted to reach the final decision. Data will be presented in narrative form and summary tables.

Risk of bias assessment

For randomized controlled trials, the risk of bias in each included study for each outcome will be evaluated independently by two reviewers, using the Cochrane Collaboration Risk of Bias in randomized trials (RoB 2.0 tool).⁴⁰ Studies will be assessed from 5 domains: bias from randomisation, bias from deviates from intended interventions, bias due to missing data, bias in outcome measurement and bias in the selection of the reported result. ⁴⁰ An overall rating of low bias, some concerns about bias or high bias will be given depending on the result of assessment. The Cochrane Risk of Bias in Non-randomized studies – of Interventions (ROBINS-1 tool) will be used to assess the risk of bias for each outcome in non-randomized comparative studies. ⁴¹Risk

BMJ Open

of Bias in Systematic Reviews (ROBIS) tool will be used to assess the risk of bias for the eligible systematic reviews.⁴²

Grading the strength of evidence

The certainty of the evidence per outcome for each comparison will be assessed from five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach and be classified into four levels of evidence (high, moderate, low or very low).⁴³

Data synthesis

All data extracted will be presented in both narrative form and in summary tables. If data is missing, the study authors will be contacted to try to obtain the data. For sleep measures investigated by two or more studies, if there are no clinical heterogeneity (e.g., different age or intervention) and methodological heterogeneity (e.g., different measurement tools), statistical heterogeneity will be assessed using Q statistic with a p value < 0.1 indicating for significant heterogeneity. The I² statistic will also be calculated with 25%, 50% and 75% representing low, medium, and high heterogeneity, respectively.⁴⁴ The heterogeneity in OC effects may be caused by differences in study populations (such as age of patients), different OC or doses received, length of follow-up, and other factors. If heterogeneity level is low or medium, we will conduct randomeffects meta-analyses to estimate the magnitude of the overall effect of OC, with 95% confidence interval depicting the uncertainty around the estimate. Subgroup analyses (e.g., by age) and sensitivity analyses (e.g., by progesterone dose) will be conducted as if sufficient data are available. As long as studies included in the systematic review form a connected network, a network meta-analysis using both direct and indirect evidence will be conducted to estimate the comparative harm of different contraceptives.⁴⁵⁻⁴⁶ Results from the network meta-analysis will

allow us to summarize and interpret a wider picture of the evidence for the putative effect of hormonal contraceptives on sleep.

DISCUSSION

Strengths and limitations

This systematic review will be the first to provide quantitative estimates of the association between hormonal contraceptives, especially OC, use and sleep outcomes in healthy women. Our systematic review methodology includes explicit eligibility criteria created in consultation with research librarians, and the usage of tested, standardized abstraction forms. We will calibrate our review methods throughout the review process for optimal consistency among reviewers. The GRADE approach will be applied to aggregate data, the PRISMA-P reporting checklist is followed to draft this systematic review protocol, and the PRISMA reporting checklist will be followed to draft this systematic review later. The κ statistic will be reported to identify issues with reproducibility. Our review will encompass a wide range of hormonal contraceptive formulations and sleep outcome measurements. We anticipate limitations with regard to publication bias and recall bias as the majority of studies employ self-administered tools to assess sleep quality and duration.

Study implications

Sleep quality is a crucial outcome that affect overall life quality in women of reproductive age and may indicate risk of developing comorbid conditions. The relationship between hormonal contraceptive use and sleep quality, duration and disorder have been reported inconsistently in the current literature. Hormonal contraceptives have been more and more widely accepted by women. However, no study has attempted to provide systematic evidence on the association between hormonal contraceptive use and sleep. Our systematic review will elucidate the association

BMJ Open

between hormonal contraceptive use and sleep quality. Moreover, it will contribute evidence that will support the improvement of guidelines for taking hormonal contraceptive in healthy women and promote awareness of safety for taking hormonal contraceptive, especially OCs.

It is challenging to design, conduct, and analyze original studies investigating the association between OC use and sleep quality. For instance, a wide variety of OC are utilized in women and they may change to other brands of OC tablets or birth control methods. In addition, most studies use subjective sleep measures, which may involve recall the information in the past. Through appraisal of published studies, our systematic review will inform the improvement in the design and implementation of future research in this field.

Conflict of Interest Disclosures: All the authors have declared no financial conflicts of interest. **Funding:** This research received no grant from any funding agency in the public, private or not-for-profit sector.

Acknowledgement: Dr. Chunxue Wang and Dr. Ning Zhang are supported by National Key Research & Development Program of China (No. 2016YFC1307200), National Key Research & Development Program of China (No. 2020YFC2005304), and Beijing Key Clinical Specialty Construction Project.

Contributors: JM, MC, XY, CW conceptualized and designed the protocol, drafted the initial manuscript and reviewed the manuscript. MC, XY, JM, QW, HK, and HR defined the concepts and search items, data extraction process as well as methodological appraisal of the study. MC, JM, QW, and XY planned the data extraction and statistical analysis. LT, CM, and NZ provided critical insights. All authors approved the final manuscript.

# Searches 1 exp contraceptive agents/ or exp hormonal contraception/ 2 exp contraception/ or fertility control.mp. or (fertiliz* adj3 inhibit*).mp. 3 exp birth control/ 4 exp family planning services/ 5 desogestrel/ or nor pregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestins.mp. or progestogen.mp. 9 lynestrenol/ 10 norrethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnenc\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenon.mp. 19 upsettrenol.mp. 20 norethindrone mp. 21 norgestrel.mp. 22 etonogestrel.mp.	Cit	ations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present
1 exp contraceptive agents/ or exp hormonal contraception/ 2 exp contraception/ or fertility control.mp. or (fertiliz* adj3 inhibit*).mp. 3 exp birth control/ 4 exp family planning services/ 5 desogestrel/ or nor pregenenes/ or progesterone congeners/ 6 exp thinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestins.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or octradiol.mp. 16 (desogestrel or norpregnenes° or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 21 norgestrel.mp. 22 etonogestrel or D-norgestrel).mp. 23 gestodene.mp. 24 (levonorgestrel or D-norge	#	Searches
2 exp contraception/ or fertility control.mp. or (fertiliz* adj3 inhibit*).mp. 3 exp birth control/ 4 exp family planning services/ 5 desogestrel/ or nor pregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestins.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or octradiol.mp. 16 (desogestrel or norpregnene& or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 nortenidrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienoge	1	exp contraceptive agents/ or exp hormonal contraception/
3 exp birth control/ 4 exp family planning services/ 5 desogestrel/ or nor pregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestins.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnenes or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28	2	exp contraception/ or fertility control.mp. or (fertiliz* adj3 inhibit*).mp.
4 exp family planning services/ 5 desogestrel/ or nor pregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norgestrel.mp. 21 norgestrel.mp. 22 etonogestrel or D-norgestrel).mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 </td <td>3</td> <td>exp birth control/</td>	3	exp birth control/
5 desogestrel/ or nor pregnenes/ or progesterone congeners/ 6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauter	4	exp family planning services/
6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. 7 dienogest.mp. 8 exp progestin/ or progestinS.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnenes or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 jutt control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contracep	5	desogestrel/ or nor pregnenes/ or progesterone congeners/
7 dienogest.mp. 8 exp progestin/ or progestin\$.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnences or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dicnogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device" mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine contraceptive device.mp.	6	exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp.
8 exp progestin/ or progestin§.mp. or progestogen.mp. 9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine contraceptive device.mp. 33 Intrauterine contracep	7	dienogest.mp.
9 lynestrenol/ 10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp.	8	exp progestin/ or progestin\$.mp. or progestogen.mp.
10 norethindrone/ 11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine contraceptive device.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iud*.mp. 35 exp Medroxyprogesterone/ o	9	lynestrenol/
11 levonorgestrel/ 12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel or D-norgestrel).mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine contraceptive device.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprog	10	norethindrone/
12 (etynodiol diacetate or ethynodiol diacetate).mp. 13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone.mp.	11	levonorgestrel/
13 norgestrel/ 14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine contraceptive device.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone.mp.	12	(etynodiol diacetate or ethynodiol diacetate).mp.
14 mestranol.mp. or exp mestranol/ 15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp.	13	norgestrel/
15 exp estradiol/ or estradiol.mp. or oetradiol.mp. 16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine contraceptive device.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp.	14	mestranol.mp. or exp mestranol/
16 (desogestrel or norpregnene\$ or progestins).mp. 17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine contraceptive device.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp.	15	exp estradiol/ or estradiol.mp. or oetradiol.mp.
17 (progesterone congeners adj2 synthetic).mp. 18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine contraceptive device.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp.	16	(desogestrel or norpregnene\$ or progestins).mp.
18 drospirenone.mp. 19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp.	17	(progesterone congeners adj2 synthetic).mp.
19 lynestrenol.mp. 20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine contraceptive device.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone.mp.	18	drospirenone.mp.
20 norethindrone.mp. 21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone.mp. or depomedroxyprogesterone.mp.	19	lynestrenol.mp.
21 norgestrel.mp. 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depo-	20	norethindrone.mp.
 22 etonogestrel.mp. 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp. 	21	norgestrel.mp.
 23 gestodene.mp. 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone.mp. 	22	etonogestrel.mp.
 24 (levonorgestrel or D-norgestrel).mp. 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp. 	23	gestodene.mp.
 25 norgestimate.mp. 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp. 	24	(levonorgestrel or D-norgestrel).mp.
 26 dienogest.mp. 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp. 	25	norgestimate.mp.
 27 contracept*.mp. 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp. 	26	dienogest.mp.
 28 birth control.mp. 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp. 	27	contracept*.mp.
 29 family planning.mp. 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp. 	28	birth control.mp.
 30 Intrauterine device.mp. or "intra uterine device".mp. 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp. 	29	family planning.mp.
 31 exp Contraceptive Devices, Female/ 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone mp. 	30	Intrauterine device.mp. or "intra uterine device".mp.
 32 Intrauterine system.mp. 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depo- medroxyprogesterone mp. or medroxyprogesterone mp. 	31	exp Contraceptive Devices, Female/
 33 Intrauterine contraceptive device.mp. 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depo- medroxyprogesterone mp. or medroxyprogesterone mp. 	32	Intrauterine system.mp.
 34 iud*.mp. or iucd*.mp. 35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depo- medroxyprogesterone mp. or medroxyprogesterone mp. 	33	Intrauterine contraceptive device.mp.
³⁵ exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depo-	34	iud*.mp. or iucd*.mp.
μποατολγμιοχοδιοτοποιτήρι οι πισατολγμιοχοδιοτοποιπίμ.	35	exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depo- medroxyprogesterone.mp. or medroxyprogesterone.mp.

38	DPMA.mp.			
39	or/1-38			
40	exp sleep/			
41	exp sleep-wake transition disorders/ or exp sleep deprivation/ or exp sleep wake disorders/ exp dyssomnias/			
42	(fragmented sleep or insufficient sleep syndrome\$).mp.			
43	exp sleep latency/ or exp sleep hygiene/			
44	exp sleep arousal disorder/			
45	exp sleep disorder/			
46	Sleep*.af.			
47	(insomnia\$ or hypersomnia\$).mp. or "disorders of excessive somnolence"/			
48	exp restless legs syndrome/ or restless legs syndrome.mp.			
49	or/40-48 \rightarrow all sleep terms			
50	(comment or letter or editorial or note or erratum or short survey or news or newspaper article or patient education handout or case reports or historical article).pt.			
51	animal/ not human/			
52	or/50=51 or/two above			
53	(39 and 49) not 52			
54	limit 53 to yr="1970-current"			

Database: Embase 1974 to 2020 August 17

Searches				
exp contraceptive agents/ or hormonal contraception/				
exp contraception/ or fertility control.mp. or fertilization inhibition.mp. or inhibition of fertilization.mp.				
exp birth control/				
exp family planning services/				
desogestrel/ or norpregnenes/ or progesterone congeners/				
exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp.				
dienogest.mp.				
exp progestin/ or progestin\$.mp. or progestogen.mp.				
lynestrenol/				
norethindrone/				
norgestrel/				
levonorgestrel/				
(etynodiol diacetate or ethynodiol diacetate).mp.				
mestranol.mp. or exp mestranol/				
exp estradiol/ or estradiol.mp. or oetradiol.mp.				
(desogestrel or norpregnene\$ or progestins).mp.				

18	drospirenone.mp.
19	lynestrenol.mp.
20	norethindrone.mp.
21	norgestrel.mp.
22	etonogestrel.mp.
23	gestodene.mp.
24	(levonorgestrel or D-norgestrel).mp.
25	norgestimate.mp.
26	dienogest.mp.
27	contracept*.mp.
28	Birth Control.mp.
29	Family planning.mp.
30	Intrauterine device.mp. or "intra uterine device".mp.
31	exp Contraceptive Devices, Female/
32	Intrauterine system.mp.
33	Intrauterine contraceptive device.mp.
34	iud*.mp. or iucd*.mp.
25	exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depo-
35	medroxyprogesterone.mp. or medroxyprogesterone.mp.
36	Depo-provera.mp. or depo provera.mp.
37	(vaginal or hormon* or contraceptive) adj2 (ring or patch or injection).mp.
38	DPMA.mp.
39	or/1-38
40	exp sleep/
41	exp Sleep-Wake Transition Disorders/ or exp Sleep Deprivation/ or exp Sleep Wake Disorders/ or exp dyssomnias/
42	(fragmented sleep or insufficient sleep syndrome\$).mp.
43	exp sleep latency/ or exp sleep hygiene/
44	exp sleep arousal disorder/
45	sleep*.af.
46	(insomnia\$ or hypersomnia\$).mp. or "disorders of excessive somnolence"/
47	exp restless legs syndrome/ or restless legs syndrome.mp.
48	exp sleep disorder/
49	or/40-48
50	(editorial or note or letter erratum or short survey or abstract).pt. or abstract report/ or lett
50	or case study/
51	animal/ not human/
52	or/50-51
53	exp female/ or female\$.mp. or women.mp. or woman.mp.
54	(39 and 49 and 53) not 52

1		
2		
3	55 lii	mit 54 to yr="1970-current"
5		
6	Data	base: Cochrane Central
7	#	Searches
8	1	MeSH descriptor: [Contraceptive Agents] explode all trees
9	2	MeSH descriptor: [Hormonal Contraception] explode all trees
10 11	3	MeSH descriptor: [Contraception] explode all trees
12	4	Fertility Control
13	5	Fertilization inhibition
14	6	inhibition of fortilization
15	0	MaSU decomination [Femily Disprine Services] symbols all trace
16	/	MeSH descriptor. [Family Planning Services] explode all trees
17	8	MeSH descriptor: [Desogestrel] this term only
18	9	MeSH descriptor: [Norpregnenes] this term only
20	10	MeSH descriptor: [Progesterone Congeners] this term only
21	11	MeSH descriptor: [Ethinyl Estradiol] explode all trees
22	12	ethinyl estradiol
23	13	ethinylestradiol
24	14	dienogest
25	15	MeSH descriptor: [Progestins] explode all trees
26	16	progestin
27	10	progesting
29	1/	M-SUL descriptore [Lemestrene1] this term on he
30	18	MeSH descriptor: [Lynestrenol] this term only
31	19	MeSH descriptor: [Norethindrone] this term only
32	20	MeSH descriptor: [Norgestrel] this term only
33	21	MeSH descriptor: [Levonorgestrel] this term only
34	22	Etynodiol diacetate
35	23	mestranol
30	24	MeSH descriptor: [Mestranol] explode all trees
38	25	MeSH descriptor: [Estradio]] explode all trees
39	26	estradiol
40	20	ostradiol
41	27	(despectral or normagnana [®] or progesting)
42	20	
43 11	29	progesterone congeners adj2 synthetic
45	30	drospirenone
46	31	lynestrenol
47	32	norethindrone
48	33	norgestrel
49	34	etonogestrel
50 51	35	gestodene
52	36	levonorgestrel
53	37	norgestimate
54	38	dienogest
55	30	contracent*
56	57	contracept
57		
50 50		20
55		

~	
2	
2	
3	
Λ	
4	
5	
-	
6	
7	
/	
8	
0	
9	
10	
11	
11	
12	
12	
13	
14	
15	
15	
16	
10	
17	
10	
18	
10	
19	
20	
20	
21	
22	
22	
23	
24	
27	
25	
26	
27	
27	
28	
20	
29	
30	
21	
51	
32	
52	
33	
34	
25	
22	
36	
50	
37	
20	
38	
20	
22	
40	
41	
42	
42	
43	
τJ	
44	
45	
16	
46	
17	
47	
48	
49	
FO	
50	
51	
51	
52	
53	
Г 4	
54	
55	
رر	
56	
57	
E 0	
58	
50	
72	

40	birth control
41	family planning
42	MeSH descriptor: [Intrauterine device] this term only
43	Intrauterine device
44	Intrauterine system
45	Intrauterine contraceptive device
46	Iud
47	d-norgestrel
48	iucd
49	Depotmedroxyprogesterone
50	depo-medroxyprogesterone
51	medroxyprogesterone
52	Depo-provera
53	depo provera
54	DPMA
55	Vaginal ring/
56	Ethyndiol diacetate
57	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or
	18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or
	33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or
50	48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56
50	MeSH descriptor: [Sleep] explode all trees
59	MeSH descriptor: [Sleep-wake Transition Disorders] explode all trees
60	MeSH descriptor: [Sleep Deprivation] explode all trees
01 ()	MeSH descriptor. [Steep wake Disorders] explode all trees
62	mesh descriptor. [Dyssomnias] explode all trees
03	Masti descriptory [Slace Userional cyrlade all trace
64	MeSH descriptor: [Sleep Hygiene] explode all trees
65	MeSH descriptor. [Sleep Latency] explode all trees
00 67	MeSH descriptor. [Steep Arousal Disorders] explode all trees
0/	sieep*
68	insomnias or hypersomnias
09 70	disorders of excessive somnolence
/0	MeSH descriptor: [Restless Legs Syndrome] explode all trees
/1	results registed by the result of the resul
72	380139010001010102010301040103010001070108010901700171
13	(comment or fetter or editorial of note of erratum of short survey of news of newspaper article or national article) at
74	MeSH descriptor: [Animals] explode all trees
75	MeSH descriptor: [Humans] explode all trees
76	73 and 74 not 75
77	(57 and 72) not 76
78	limit 77 to vr="1970-current"
10	

REFI	ERENCES
1.	Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM,
	Stijnen T, et al. Different combined oral contraceptives and the risk of venous
	thrombosis: systematic review and network meta-analysis. BMJ. [Internet]. 2013 Sep 12
	[cited 2020 Jul 20]; 347(sep12 1):f5298–f5298. Available from:
	https://pubmed.ncbi.nlm.nih.gov/24030561/
2.	Dhont M. History of oral contraception. Eur J Contracept Reprod Health Care [Internet]
	2010 Dec [cited 2020 Jul 20];15 Suppl 2:S12-18. Available from:
	https://pubmed.ncbi.nlm.nih.gov/21091163/
3.	LeBlanc ES, Laws A. Benefits and Risks of Third-Generation Oral Contraceptives. J G
	Intern Med [Internet]. 1999 Oct [cited 2020 Jul 20];14(10):625–32. Available from:
	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1496751/
4.	Davtyan C. Four Generations of Progestins in Oral Contraceptives. Proceedings of
	UCLA Healthcare [Internet]. 2012 [cited 15 May 2020];16. Available from:
	https://proceedings.med.ucla.edu/index.php/2012/09/12/four-generations-of-progestins-
	-oral-contraceptives/
5.	United Nations. Contraceptive Use by Method 2019: Data Booklet [Internet]. UN; 201
	[cited 2020 Jul 20]. Available from: https://www.un-ilibrary.org/population-and-
	demography/contraceptive-use-by-method-2019_1bd58a10-en
6.	van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of
	ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the
	vaginal ring, the transdermal patch and an oral contraceptive. Contraception [Internet].
	2005 Sep;72(3)[cited 2021 March 1]:168–74. Available from:
	https://pubmed.ncbi.nlm.nih.gov/16102549/
7.	Dean, Gillian; Schwarz, Eleanor Bimla (2011). "Intrauterine contraceptives (IUCs)". In
	Hatcher, Robert A.; Trussell, James; Nelson, Anita L.; Cates, Willard Jr.; Kowal,
	Deborah: Policar, Michael S. (eds.), Contraceptive technology (20th revised ed.), New
	York: Ardent Media, pp. 147–191.
	# # * * * * * * * * * * * * * *
	22
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

8. Palomba S, Falbo A, Cello AD, Materazzo C, Zullo F. Nexplanon: the new implant for long-term contraception. A comprehensive descriptive review. Gynecological Endocrinology [Internet]. 2012 Sep 1[cited Feb 26];28(9):710–21 Available from: https://pubmed.ncbi.nlm.nih.gov/22339096/ 9. Lancel M, Faulhaber J, Schiffelholz T, Romeo E, Di Michele F, Holsboer F, et al. Allopregnanolone affects sleep in a benzodiazepine-like fashion. J Pharmacol Exp Ther [Internet]. 1997 Sep [cited 2020 Jul 20] ;282(3):1213–8. Available from: https://pubmed.ncbi.nlm.nih.gov/9316828/ 10. Allada R, Cirelli C, Sehgal A. Molecular Mechanisms of Sleep Homeostasis in Flies and Mammals. Cold Spring Harb Perspect Biol [Internet]. 2017 Aug 1[cited 2020 Jul 20];9(8). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538413/Schwartz MD, Mong JA. 11. Estradiol modulates recovery of REM sleep in a time-of-day-dependent manner. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2013 May 15;305(3):R271-80. 12. Bezerra AG, Andersen ML, Pires GN, Tufik S, Hachul H. Effects of hormonal contraceptives on sleep - A possible treatment for insomnia in premenopausal women. Sleep Sci [Internet]. 2018 Jun [cited 2020 Jul 20];11(3):129–36. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201525/ 13. Léger D, Bayon V. Societal costs of insomnia. Sleep Med Rev. 2010;14(6):379-89. 14. Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16(5):873-97; discussion 854. 15. Gourineni R. Prognosis and complications. In: Attarian HP, ed. Clinical Handbook of Insomnia. 3rd ed. New York: Springer; 2017. p. 59-73. 16. Kessler, R.C., Berglund, P.A., Coulouvrat, C., Hajak, G., Roth, T., Shahly, V., et al. (2011). Insomnia and the performance of US workers: results from the America insomnia survey. Sleep; 34(9): 1161–1171. 17. Ohayon, M.M., O'Hara, R., Vitiello, M.V. (2012). Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Medicine Reviews; 16(4): 283-295.

BMJ Open

	(2016). Obstructive Sleep Apnea in Women: Specific Issues and Interventions. Biomed
	Research International; 2016: 1764837.
19.	Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. In:
	Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al.,
	editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited
	2020 Sep 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK279054/
20.	Baker FC, Lee KA. Menstrual Cycle Effects on Sleep. Sleep Med Clin [Internet]. 2018
	Sep[cited 2021 Mar 1];13(3):283–94.
21.	Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives
	and intrauterine contraceptive devices. Am J Obstet Gynecol [Internet]. 1999 Nov [cited
	2020 Jul 20] ;181(5 Pt 1):1263-9. Available from:
	https://pubmed.ncbi.nlm.nih.gov/10561657/
22.	Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al.
	Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial
	Cancers: A Systematic Review. Cancer Epidemiol Biomarkers Prev [Internet]. 2013 Nov
	1 [cited 2020 Jul 20];22(11):1931–43. Available from:
	https://pubmed.ncbi.nlm.nih.gov/24014598/
3.	Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral
	contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb
	Haemost [Internet]. 1997 Jul [cited 2020 Jul 20] ;78(1):327–33. Available from:
	https://pubmed.ncbi.nlm.nih.gov/9198174/
24.	Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk
	and combined oral contraceptives: the Royal College of General Practitioners' Oral
	Contraception Study. American Journal of Obstetrics and Gynecology [Internet] . 2017
	Jun 1 [cited 2020 Jul 20] ;216(6):580.e1-580.e9. Available from:
	https://pubmed.ncbi.nlm.nih.gov/28188769/
25.	Liu H, Yao J, Wang W, Zhang D. Association between duration of oral contraceptive use
	and risk of hypertension: A meta-analysis. J Clin Hypertens (Greenwich) [Internet]. 2017
	Oct [cited 2020 Jul 20];19(10):1032–41. Available from:
	https://pubmed.ncbi.nlm.nih.gov/28612347/
	24
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 26. Guida M, Rega A, Vivone I, Saccone G, Sarno L, Di Carlo C, et al. Variations in sleep associated with different types of hormonal contraceptives. Gynecol Endocrinol [Internet]. 2020 Feb [cited 2020 Jul 20] ;36(2):166–70. Available from: https://pubmed.ncbi.nlm.nih.gov/31311352/
- 27. Hachul H, Andersen ML, Bittencourt L, Santos-Silva R, Tufik S. A population-based survey on the influence of the menstrual cycle and the use of hormonal contraceptives on sleep patterns in São Paulo, Brazil. Int J Gynaecol Obstet [Internet]. 2013 Feb[cited 2020 Jul 20];120(2):137–40. Available from:

https://www.sciencedirect.com/science/article/abs/pii/S0020729212005619

- 28. Lundin C, Danielsson KG, Bixo M, Moby L, Bengtsdotter H, Jawad I, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology [Internet]. 2017[cited 2020 Jul 20];76:135–43. Available from: https://pubmed.ncbi.nlm.nih.gov/27923181/
- 29. Bezerra AG, Andersen ML, Pires GN, Banzoli CV, Polesel DN, Tufik S, et al. Hormonal contraceptive use and subjective sleep reports in women: An online survey. J Sleep Res [Internet]. 2020 Jan 27 [cited 2020 Jul 20] ;e12983. Available from: https://pubmed.ncbi.nlm.nih.gov/31989746/
- Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., ... & Stewart, L. A. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews, 4(1), 1.
- 31. Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225-34.
- 32. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. Natl Health Stat Report [Internet].2012 Oct 18;(60):1–25.Available from:

https://pubmed.ncbi.nlm.nih.gov/24988814/#:~:text=Use%20of%20intrauterine%20devic es%20as,current%2C%20most%20effective%20contraceptive%20method.

BMJ Open

	patterns in adolescents. Asian J Psychiatr [Internet]. 2009 Mar 1;2(1):17-24. Available
	from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786078/
34.	Grandner MA, Patel NP, Gehrman PR, Xie D, Sha D, Weaver T, et al. Who Gets the
	Sleep? Ethnic and Socioeconomic Factors Related to Sleep Complaints. Sleep Med
	[Internet]. 2010 May;11(5):470-8. Available from:
	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861987/
35.	Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep
	Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res
	[Internet]. 1989 May [cited 2020 Jul 20] ;28(2):193–213. Available from:
	https://pubmed.ncbi.nlm.nih.gov/2748771/
36.	Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness
	scale. Sleep [Internet]. 1991 Dec [cited 2020 Jul 20];14(6):540–5. Available from:
	https://pubmed.ncbi.nlm.nih.gov/1798888/
37.	Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of a
	instrument based on ICD-10 criteria. Journal of Psychosomatic Research [Internet].
	2000[cited 2020 July 20] ;48:555-60. Available from:
	https://pubmed.ncbi.nlm.nih.gov/11033374/
38.	The Insomnia Severity Index: Psychometric Indicators to Detect Insomnia Cases and
	Evaluate Treatment Response [Internet]. [cited 2020 Jul 20]. Available from:
	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079939/
39.	Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of
	administration. Climacteric [Internet]. 2005 Aug [cited 2021 March 1];8 Suppl 1:3-63
	Available from: https://pubmed.ncbi.nlm.nih.gov/16112947/
40.	Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
	revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 Aug
	[cited 2020 Sep 28];366. Available from: https://www.bmj.com/content/366/bmj.1489
41.	Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
	revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 [cited
	2020 Jul 20]; 28;366:14898. Available from: https://pubmed.ncbi.nlm.nih.gov/314625

- 42. Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225-34.
 - 43. Schünemann HJ, Brożek J, Guyatt G, Oxman A. GRADE handbook [Internet]. GRADE Handbook. 2013 [cited 2020 Sep 28]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html
 - 44. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003 Sep 4;327(7414):557–60.
 - 45. Chaimani A, Caldwell DM, Li T. Chapter 11: Undertaking network meta-analyses: Higgins JPT, Thomas J, Chandler J, et al., Cochrane Handbook for Systematic Reviews of Interventions. version 6.0 (updated July 2019) Cochrane, 2019

46. Caldwell DM, Welton NJ. Approaches for synthesising complex mental health interventions in meta-analysis. Evid Based Ment Health. 2016;19(1):16–21.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

Protected by copyright, including for uses related to text and Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

2				Page
3 1			Reporting Item	Number
5	Title			ning, A
, 3 9	Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	1 trainir 1 nir
) 2 3	Update	<u>#1b</u>	If the protocol is for an update of a previous systematic review, identify as such	ng, and sim
1 5	Registration			iilar te
5 7 3		<u>#2</u>	If registered, provide the name of the registry (such as PROSPERO) and registration number	3 3 3 3
) I	Authors			
2 3 4 5	Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
5 7 3	Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the guarantor of the review	16
)		For p	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Amendments			
	<u>#4</u>	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a
Support			-
Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	16tect
Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	n/aby
Role of sponsor or funder	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	n∕ayright, ir
Introduction			nclud
Rationale	<u>#6</u>	Describe the rationale for the review in the context of what is already known	ing for use
Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	seignement Su s related to tex 7-8
Methods			t and o
Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	ur (ABES) . data mining, Al train 8-12
Information sources	<u>#9</u>	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	ing, and simila
Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	17-24 17-24
Study records - data management	<u>#11a</u>	Describe the mechanism(s) that will be used to manage records and data throughout the review	12-13 .
Study records - selection process	<u>#11b</u>	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	8-9
Study records - data	<u>#11c</u> For pe	Describe planned method of extracting data from reports (such as er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	8-9

Page 31 of 30

BMJ Open

collection process		piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	
Data items	<u>#12</u>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	13
Outcomes and	<u>#13</u>	List and define all outcomes for which data will be sought, including	13
prioritization		prioritization of main and additional outcomes, with rationale	
Risk of bias in	<u>#14</u>	Describe anticipated methods for assessing risk of bias of individual	13
individual studies		studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	י ניקייק
Data synthesis	<u>#15a</u>	Describe criteria under which study data will be quantitatively synthesised	14
Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall's τ)	14-15
Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	14
Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the type of summary planned	14
Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	14
Confidence in cumulative evidence	<u>#17</u>	Describe how the strength of the body of evidence will be assessed (such as GRADE)	14 14
The PRISMA-P elab Attribution License https://www.goodrep	ooration a CC-BY.	and explanation paper is distributed under the terms of the Creative Commons This checklist was completed on 02. March 2021 using /, a tool made by the EQUATOR Network in collaboration with Penelope.ai	5
	For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

The Relationship between Hormonal Contraceptives and Sleep among Women of Reproductive Age: A Systematic Review Protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-045819.R2
Article Type:	Protocol
Date Submitted by the Author:	30-Jun-2021
Complete List of Authors:	Ma, Jinhui; McMaster University, Department of Health Research Methods, Evidence, and Impact Cheng, Megan; McMaster University Faculty of Health Sciences, Thabane, Lehana; McMaster University, Department of Health Research Methodology, Evidence, and Impact Ma, Caihong; Peking University Third Hospital, Zhang, Ning; Beijing Tiantan Hospital, Capital Medical University, Department of Neuropsychiatry and Behavioral Neurology ; Capital Medical University, Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Wang, Qi; McMaster University, Department of Health Research Methods, Evidence, and Impact Kim, Hyunwoo; McMaster University, Department of Health Research Methods, Evidence, and Impact Reza, Hameed; McMaster University, Faculty of Science Wang, Chunxue; Beijing Tiantan Hospital, Capital Medical University; Capital Medical University, 5Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Wang, Chunxue; Beijing Tiantan Hospital, Capital Medical University; Capital Medical University, 5Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Yao, Xiaomei; McMaster University, Department of Health Research Methods, Evidence and Impact; McMaster University, Department of Health Research Methods, Evidence and Impact; McMaster University, Department of Oncology
Primary Subject Heading :	Sexual health
Secondary Subject Heading:	Public health, Research methods
Keywords:	REPRODUCTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



The Relationship between Hormonal Contraceptives and Sleep among Women of Reproductive Age: A Systematic Review Protocol

Jinhui Ma¹, Megan Cheng², Lehana Thabane¹, Caihong Ma³, Ning Zhang⁴, Qi Wang¹, Hyunwoo Kim¹, Hameed Reza⁵, Chunxue Wang⁴, Xiaomei Yao^{1,6}

¹Department of Health Research Methods, Evidence, and Impact, McMaster University,

Hamilton, Ontario, Canada

²Faculty of Health Science, McMaster University, Hamilton, Ontario, Canada

³Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking

University Third Hospital, Beijing, China

⁴Department of Neuropsychiatry and Behavioral Neurology, Beijing Tiantan Hospital, Capital

Medical University, Beijing, China

⁵Faculty of Science, McMaster University, Hamilton, Ontario, Canada

⁶Center for Clinical Practice Guideline Conduction and Evaluation, Children's Hospital of Fudan

University, Shanghai, China

Corresponding:

Xiaomei Yao: 711 Concession Street, Hamilton, L8V 1C3, ON, Canada, Tel: +1-9055274322

ext. 42824, E-mail: yaoxia@mcmaster.ca

Chunxue Wang: No. 119 South Fourth Ring West Road, Fengtai District, Beijing 100070, P.R.

China ,Tel: +01186-13701193710, E-mail: snowsen@126.com

ABSTRACT

Introduction The exact etiology of sleep disruptions is unknown but hormonal fluctuations during the menstrual cycle, pregnancy, and menopause have been shown to potentially affect how well a woman sleeps. The aim of this systematic review is to investigate whether hormonal contraceptives are associated with a decreased quality of sleep and increased sleep duration in women of reproductive age.

Methods This review will analyze data from randomized controlled trials or non-randomized comparative studies investigating the association between hormonal contraceptives and sleeprelated outcomes among women of reproductive age, including sleep quality and sleep disorders. Reviews addressing the same research question with similar inclusion/exclusion criteria will be included. A literature search will be performed using the MEDLINE, EMBASE and Cochrane CENTRAL databases. The Cochrane Collaboration's Risk of Bias for Randomised Trials (RoB 2.0) and The Cochrane Risk of Bias for Non-randomized studies – of Interventions (ROBINS-1 tool) will be used to assess risk of bias for each outcome in eligible studies. Two reviewers will independently assess eligibility of studies, risk of bias and extract the data. A third author will solve discrepancies. All extracted data will be presented in summary tables and narrative form. For sleep measures investigated by two or more studies with low heterogeneity, we will conduct random-effects meta-analysis to estimate the magnitude of the overall effect of hormonal contraceptives. If studies included in this systematic review form a connected network, a network meta-analysis will be conducted to estimate the comparative effect of different contraceptives. The GRADE approach will be used to summarise the quality of evidence. Our protocol follows the

Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols 2015

(PRISMA-P 2015) guidelines.

Keywords: hormonal contraceptive, oral contraceptive, contraception, sleep quality, sleep duration **Ethics and dissemination:** Ethics approval is not required as we analyze data from previously

reported studies.

PROSPERO registration number: CRD42020199958.

Article Summary

Strengths and Limitations of this study:

- This systematic review on the association between hormonal contraceptive use and sleep is based on a robust, librarian consulted search strategy.
- The literature review, data extraction, and risk of bias assessment are performed by two independent reviewers to mitigate bias.
- The risk of bias of each outcome from included papers will be assessed with the appropriate tool.
- Papers in languages other than English are not included, leading to potential for language bias.

Word Count: 3633

INTRODUCTION

Worldwide, there are around 1.9 billion women of reproductive age. Hormonal contraceptives including oral contraceptives (OC), vaginal ring, contraceptive skin patches, implants, injections, and hormonal intrauterine contraceptive devices (IUDs), are widely used around the world in women of reproductive age to avoid unintentional pregnancy.¹ Of the 842 million women using modern forms of contraception, 43% are using hormonal contraceptives. The overall number of users of hormonal contraceptives is increasing annually.¹ One hundred and fiftyone million women use OCs with usage varying by region.¹ Other hormonal contraceptives such as implants, vaginal rings, and intrauterine devices have been widely adopted as well and used by over 256 million women in the world.¹ These hormonal contraceptives have different dosage, formulation, mechanism of action, and applicable groups compared to OCs.² Unlike OCs which are taken consistently and provide a stable dosage of the estrogen and progestin components, other hormonal contraceptives have the potential to provide lower dose of progestin and estrogen. It has been shown that hormonal IUDs release levonorgestrel directly into the uterus, only a small amount is absorbed into the rest of the body, thus its effects are mostly paracrine rather than systemic.³

Progesterone, a primary component in hormonal contraceptives, is an agonist of gammaaminobutyric acid (GABA) receptors through a metabolite, allopregnanolone. ⁴GABA is a crucial molecule in sleep promotion – most sleep-promoting neurons are sensitive to GABA. ⁵ Common sleep medications, such as benzodiazepines have been shown to positively modulate GABA signalling.⁵ The potency of progestin is comparable to that of benzodiazepines and has similar agonistic effects. Changes in electroencephalogram activity seen with progesterone administration

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

are similar to those evoked by benzodiazepines.⁴ Studies in rat models have shown that administration of exogenous progesterone leads to dose-dependent decreased sleep latency and wakefulness.⁴ The mechanism behind the effect of estrogen on sleep is not well elucidated but rat studies have shown that administration of estrogen promotes sleep during the sleep period and reduces sleep during the wakefulness period.⁶ The overall effect on sleep is likely caused by a combination of both estrogen and progesterone, although the magnitude of their contribution to sleep changes is unknown.⁷ High quality sleep is as essential as regular exercise and eating a balanced diet for maintenance of ontimal health and well-being. Severe sleeping problems, such as insomnia, are

maintenance of optimal health and well-being. Severe sleeping problems, such as insomnia, are important matters from both a public health perspective and an individual level. Insomnia is associated with depression, anxiety, substance abuse, cognitive impairment, metabolic disorders (e.g., diabetes, dyslipidemia, and obesity) and cardiovascular diseases.⁸⁻¹⁰ Women are more likely than men to have sleep problems including insomnia and restless leg syndrome. The exact etiology of these sleep disruptions is unknown but hormonal fluctuations during the menstrual cycle, pregnancy, and menopause have been shown to potentially affect how well a woman sleeps.¹¹⁻¹³ During ovulation, there is a surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which leads to a decrease in estrogen concentration and an increase in progesterone.¹⁴ During the luteal phase, progesterone concentrations increase and estrogen levels are high up to the mid-phase. Starting from the mid-luteal phase, both estrogen and progesterone levels decrease.¹⁴ Sleep disturbances are most commonly reported at the end of the luteal phase and early follicular phase.¹⁵ OCs are taken each day for 21 days, providing a constant, exogenous source of estrogen and progesterone, preventing the release of FSH and LH and thus the production of a

BMJ Open

follicle or ovulation.¹⁶ Therefore, hormonal contraceptives may affect women's sleep-wake cycle and cause physiological changes that lead to sleep disturbance.

Unlike other commonly prescribed drugs, hormonal contraceptives are used by healthy women for long periods of time. Safety trials of hormonal contraceptives have focussed largely on breast cancer and venous thromboembolism risk. ¹⁷⁻¹⁹ Despite decreases in estrogen concentration with later OC generations, its use has been shown to be associated with an increased risk of developing breast cancer and venous thromboembolism.²⁰ A 2017 cohort study found OC intake was associated with a reduced risk of colorectal, endometrial and ovarian cancers and increased risk of cervical and breast cancer.²¹ Studies in women have varied findings on the association between hormonal contraceptive use and sleep quality and duration. Differences in methodology, including the formulation of contraceptives taken, stratification of formulations, measurements of sleep, or the phase of the menstrual cycle of naturally cycling women used as comparison may explain the different findings between studies. For instance, a pilot study published in 2020 by Guida *et al* found significantly increased sleep duration for users of oral progestins, oral gestodene and 13.5 mg levonorgestrel intrauterine systems, compared with naturally cycling women (women not currently using any hormonal contraceptive), and decreased sleep latency and better sleep quality for users of depot-administered contraceptives.²² However, a polysomnography study published in 2012 by Hachul et al found decreased sleep latency in women using OC and no difference in overall sleep quality.²³ A randomized control trial by Lundin et al found no significant sleep related results, while a cross sectional analysis by Bezerra *et al* found that hormonal contraceptive users had worse sleep quality compared with their naturally cycling counterparts.²⁴⁻

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Given the high prevalence of hormonal contraceptive use among women of reproductive age and the relationship between hormonal contraceptive use and sleep varying in both magnitude and direction in the current literature, there is an urgent need to provide women with accurate, evidence-based information to inform their use of hormonal contraception.²²⁻²⁵ Hence, the objective of this systematic review is to compile and elucidate the association between hormonal contraceptive use and sleep (including the quality of sleep, sleep disorders, and duration of sleep). Our hypothesis is hormonal contraceptives are associated with a decreased quality of sleep and increased sleep duration in women of reproductive age. Findings from this review will provide insights to women choosing between different methods and formulations, while also inform the development of new progestins for future generations of hormonal contraceptives. The systematic review protocol was registered at the website of the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD42020199958).

METHODS

Our protocol follows the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015) guidelines.²⁶

Patient and Public Involvement

No patients were involved in this protocol.

Literature search

We developed a comprehensive search strategy with input from a research librarian at McMaster University. The systematic search for existing relevant systematic review and original studies will be conducted in the Ovid MEDLINE and Embase (Excerpta Medica dataBASE) electronic databases, and the Cochrane Library (including Cochrane Database of Systematic

Reviews and Cochrane Central Register of Controlled Trials). Search terms will cover all words related to birth control, ingredients of oral contraceptives, hormonal contraceptives, menstrual cycle, and sleep. We will limit the search to studies or systematic reviews published from 1970 to present to ensure that we include all published studies or reviewes on hormonal contraceptives, excluding first generation oral contraceptives which had been discontinued after 1970s. For sleep outcome measures, we will search sleep terms in multi-purpose fields besides the title and abstract in case sleep is investigated as a secondary outcome and therefore not reported in the abstract. The comprehensive search strategies for each database are presented in Table 1. The reference lists of all included studies will be checked to identify additional potentially eligible studies.

Study Selection and Screening

Systematic screening of the studies will be first conducted at the title and abstract level, and then at the full-text level to determine if a study meets eligibility criteria by two independent reviewers. Any potential conflicts between the reviewers will be resolved through discussion. If discrepancies in judgment remain after discussion, a third-party reviewer will be consulted to resolve the conflict and provide a final decision. BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Eligibility criteria

(1) Study Characteristics

Existing systematic reviews will be included if they (i) address the same research question with similar inclusion and exclusion criteria as ours; and (ii) have a low risk of bias in study eligibility criteria, identification and selection of studies, data collection and study appraisal, and synthesis and findings assessed using the Risk of Bias in Systematic Reviews (ROBIS) tool.²⁷

For original studies, we will include (i) randomized controlled trials, and non-randomized comparative studies that take into account the effect of potential confounders (e.g., age, race, and
Page 10 of 31

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

socioeconomic status)²⁸⁻³⁰ using methods such as multivariable analysis, propensity-score matching, or showing no statistically significant differences in baseline characteristics between participants in comparison groups; (ii) studies on human participants; and (iii) studies which investigate the association between hormonal contraceptive use and sleep-related outcomes, either as the primary or secondary objective.

(2) Participants

Participants or subgroups of participants are females between 15 and 49 years old.

(3) Exposure

Participants who take second generation or more recent OC or other hormonal contraceptives containing both progesterone and estrogen or progesterone only, regardless of its brand, dose, and frequency, to avoid pregnancy, as long as their hormonal contraceptive use pattern is sustained for at least three months by the time sleep outcomes are assessed. The first three months of hormonal contraception use or discontinuation of hormonal contraception are excluded to account for altered menstruation that occurs following discontinuation of hormonal contraception.³¹⁻³²

(4) Comparator

Included studies must have comparison groups of women who are using (i) non-hormonal contraceptives; (ii) naturally cycling (i.e., not use any contraceptive methods) or placebo; (iii) same agent as the exposure but in different dose, frequency, and duration; and (iv) second generation or more recent OC or other hormonal contraceptives different from the exposure. Since recent usage or cessation of hormonal contraceptive use may cause hormonal oscillations, we will only include studies with participants keeping their contraceptive use pattern (either using different hormonal

BMJ Open

contraceptives from the exposure or placebo, or not using any hormonal contraceptive) for at least three months by the time sleep outcomes are assessed.

(5) Outcomes

We are interested in any sleep-related outcomes assessed at any time points after keeping their contraceptive use pattern for at least three months. A variety of sleep measurements for sleep quality, sleep duration, and sleep disorder will be included in this systematic review. The sleep measurements can be questionnaires based on Likert Scale items listed below but not limited to these tools:

- (i) The Pittsburgh Sleep Quality Index (PSQI). ³³ It measures seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction over the last four weeks. The PSQI is a subjective measure of sleep. Subjects self-rate each of the seven domains of sleep from 0 to 3, where 3 represents the negative extreme on the Likert Scale. A subject with a global sum of 5 or greater is considered as a poor sleeper. Studies reported sleep quality in any of the above seven domains during and after taking hormonal contraceptives will be included in the review.
- (ii) The Epworth Sleepiness Scale (ESS) is a self-administered test used to assess daytime sleepiness.³⁴ It consists of 8 questions with different scenarios and a scale from 0-3 where subjects would indicate how likely they are to fall asleep in that situation. The scores are summed for a total score between 0 and 24. ³⁴ Studies reporting sleepiness with any of the 8 questions during and after taking hormonal contraceptives will be included in the review.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

- (iii) The Athens Insomnia Scale (AIS), which is also a self-administered psychometric instrument designed for quantifying sleep difficulty.³⁵ The AIS consists of eight items: sleep induction (i.e., time to fall asleep after turning-off the lights), night awakenings, final awakening earlier than desired, total sleep duration, overall quality of sleep, sense of well-being during the day, functioning (physical and mental) during the day, and sleepiness during the day. Each item is rated from 0 to 3 with higher scores indicating more impaired sleep. The total score ranges from 0 to 24 and a total score of 6 or more is considered as insomnia. Studies which report any or all of the above eight insomniarelated items during and after taking hormonal contraceptives will be included in the review.
- (iv) The Insomnia Severity Index (ISI), a self-administered questionnaire used to assess insomnia.³⁶ The ISI consists has a one month recall period and assesses 7 domains: severity of sleep onset, sleep maintenance, difficultly waking up in the morning, sleep dissatisfaction, interference of sleep with daytime functioning, noticeability of sleep problems by others, and distress caused by sleep difficulties. Each domain is rated on a scale from 0 to 4 with higher scores indicating more problematic sleep. The score is summed forming a total score between 0 and 28, with a score of 8 and above indicative of insomnia.³⁶ Studies reporting any domains from the ISI during and after taking hormonal contraceptives will be included in the review.

We will also include continuous measures of sleep quality and disorder. These measures include: (i) total amount of sleep obtained, either during nocturnal sleep episode or across the 24-hour period; (ii) sleep latency, i.e., how long it takes the participant to fall asleep; (iii) how many times the participant wakes up; (iv) how many minutes the participant is awake during the night;

(v) sleep efficiency, i.e., what percentage of time spent in bed the participant is actually asleep. The total sleep time is equal to the total amount of time spent in bed (in minutes) minus the sum of time it takes to fall asleep, and the time spent awake throughout the night. The percentage is calculated as the total sleep time divided by total time in bed. Given we will only include studies with participants keeping their contraceptive use pattern for at least three months, the sleep outcomes from the eligible studies will be summarized after participants keeping their contraceptive use pattern for at least three months as well.

Exclusion criteria

The following studies will be excluded from this systematic review: (1) studies only recruited patients with specific comorbidities or conditions, such as hormonal disorder, acne, perimenopause, postmenopause, dysmenorrhea, depression etc., since these conditions may be associated with sleep problems and will not allow us to elucidate the association between hormonal contraceptives and sleep; (2) studies investigating the first-generation OC since it is not available in the market anymore due to severe side effects; (3) studies investigating emergency contraception; and (4) studies in languages other than English. We will exclude emergency contraception from this review as the hormonal effect of the emergency contraception is significantly different from long-acting contraception. The half-life of oral leovnoregestrel is around 24-32 hours, which is not significant when considering long-term effect on sleep.³⁷

Data abstraction

A standard form will be developed to extract data from the included studies. From each article, the author, study design, study population, publication year, journal, participant

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

tables. Risk of bias assessment

demographics, hormonal contraceptive used, intervention details, comparison groups, sleep outcomes, and the association between hormonal contraceptive use and sleep will be extracted. Additionally, any mean values, standard deviation and confidence intervals, and all information needed for appraisal of internal validity will be extracted. This will be done in a standardized data extraction form by two reviewers independently. When consensus is not reached, a third researcher will be consulted to reach the final decision. Data will be presented in narrative form and summary

For randomized controlled trials, the risk of bias in each included study for each outcome will be evaluated independently by two reviewers, using the Cochrane Collaboration Risk of Bias in randomized trials (RoB 2.0 tool).³⁸ Studies will be assessed from 5 domains: bias from randomisation, bias from deviates from intended interventions, bias due to missing data, bias in outcome measurement and bias in the selection of the reported result.³⁸ An overall rating of low bias, some concerns about bias, or high bias will be given depending on the result of assessment. The Cochrane Risk of Bias in Non-randomized studies – of Interventions (ROBINS-1 tool) will be used to assess the risk of bias for each outcome in non-randomized comparative studies.³⁹ Studies will be assessed from 7 domains: bias due to confounding, bias in selection of participants into the study, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement outcomes, and bias in selection of the reported result. Risk of Bias in Systematic Reviews (ROBIS) tool will be used to assess the risk of bias for the eligible systematic reviews.⁴⁰ Reviews will be assessed from four domains: study eligibility criteria, identification and selection of studies, data collection and study appraisal, and

BMJ Open

synthesis and findings. We will also assess the overall risk of bias in the interpretation of review findings and whether this considered limitations identified in any of the above 4 domains.

Grading the strength of evidence

The certainty of the evidence per outcome for each comparison will be assessed from five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach and be classified into four levels of evidence (high, moderate, low or very low).⁴¹

Data synthesis

All data extracted will be presented in both narrative form and in summary tables. If data are missing, the study authors will be contacted to attempt to obtain the data. For sleep measures investigated by two or more studies, if there is no clinical heterogeneity (e.g., different age or intervention) and methodological heterogeneity (e.g., different measurement tools), statistical heterogeneity will be assessed using forest plot visually, the chi-square test of homogeneity (p value < 0.05), and quantified using the Higgins' I² statistic with 25%, 50% and 75% representing low, medium, and high heterogeneity, respectively.⁴² The presence of publication bias will be evaluated using a funnel plot and the Duval and Tweedie's trim and fill method.⁴³

We will use frequentist approach to estimate the overall effect of hormonal contraceptives on sleep. For binary outcome measures, we will express the results of each study as a risk ratio (RR) and its 95% confidence interval (CI). We will perform meta-analyses of pooling the RRs with 95% CIs of studies using a random-effects model, because of anticipated heterogeneity of hormonal contraceptives, study designs, and participants. For continuous outcome measures, standardized mean differences (SMDs) will be used for the final assessment from individual studies due to the likely variability in the measuring scales. The SMD will be categorized as small,

medium, and large based on the thresholds 0.2, 0.5 and 0.8, respectively, as suggested by Cohen's.⁴⁴ The 95% CI will be used to represent the deviation from the point estimate for both the individual studies and the pooled estimate. Random-effects meta-analysis will be used to obtain the pooled estimates. If sleep outcomes are measured at multiple time points in a study, the measure done at the similar time point as the other studies will be used in the primary meta-analysis. The outcome measured at other time points will be considered in the subgroup analysis by duration of hormonal contraceptives.

We will run subgroup analyses by hormonal method of contraception (implant, IUD, injections, pills, vaginal rings, or skin patches), agent (progesterone and estrogen combined or progesterone only), dose, and duration of contraceptives. We will run sensitivity analyses to assess whether our conclusions will be robust if excluding studies with high risk of bias and nonrandomized comparative studies. As long as studies included in the systematic review form a connected network, a network meta-analysis using both direct and indirect evidence will be conducted to estimate the comparative harm of different contraceptives.⁴⁵⁻⁴⁶ Results from the network meta-analysis will allow us to summarize and interpret a wider picture of the evidence for the putative effect of hormonal contraceptives on sleep. We will conduct data analysis using the Cochrane Collaboration Review Manager statistical software (Version 5.4.1) (http://ims.cochrane.org/RevMan).

DISCUSSION

Strengths and limitations

This systematic review will be the first to provide quantitative estimates of the association between hormonal contraceptive use and sleep outcomes in healthy women. Our systematic review methodology includes explicit eligibility criteria created in consultation with research librarians, Page 17 of 31

BMJ Open

and the usage of tested, standardized abstraction forms. We will calibrate our review methods throughout the review process for optimal consistency among reviewers. The GRADE approach will be applied to aggregate data, the PRISMA-P reporting checklist is followed to draft this systematic review protocol, and the PRISMA reporting checklist will be followed to draft this systematic review later. The κ statistic will be reported to identify issues with reproducibility. Our review will encompass a wide range of hormonal contraceptive formulations and sleep outcome measurements. We anticipate limitations with regard to publication bias and recall bias as the majority of studies employ self-administered tools to assess sleep quality and duration.

Study implications

Sleep quality is a crucial outcome that affect overall life quality in women of reproductive age and may indicate risk of developing comorbid conditions. The relationship between hormonal contraceptive use and sleep quality, duration and disorder have been reported inconsistently in the current literature. Hormonal contraceptives have been more and more widely accepted by women. However, no study has attempted to provide systematic evidence on the association between hormonal contraceptive use and sleep. Our systematic review will elucidate the association between hormonal contraceptive use and sleep quality. Moreover, it will contribute evidence that will support the improvement of guidelines for taking hormonal contraceptive in healthy women and promote awareness of safety for taking hormonal contraceptive.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

It is challenging to design, conduct, and analyze original studies investigating the association between hormonal contraceptive use and sleep quality. For instance, a wide variety of hormonal contraceptives are utilized by women who may change to other brands of contraceptive or birth control methods. In addition, most studies use subjective sleep measures, which may involve recall the information in the past. Through appraisal of published studies, our systematic

review will inform the improvement in the design and implementation of future research in this field.

Conflict of Interest Disclosures: All the authors have declared no financial conflicts of interest. **Funding:** This research received no grant from any funding agency in the public, private or not-for-profit sector.

Acknowledgement: Dr. Chunxue Wang and Dr. Ning Zhang are supported by National Key Research & Development Program of China (No. 2016YFC1307200), National Key Research & Development Program of China (No. 2020YFC2005304), and Beijing Key Clinical Specialty Construction Project.

Author Contributions: JM, MC, XY, CW conceptualized and designed the protocol, drafted the initial manuscript and reviewed the manuscript. MC, XY, JM, QW, HK, and HR defined the concepts and search items, data extraction process as well as methodological appraisal of the study. MC, JM, QW, and XY planned the data extraction and statistical analysis. LT, CM, and NZ provided critical insights. All authors approved the final manuscript.

Table 1: Search Strategies for OVID Medline, Embase and Cochrane Central
Database(s): OVID Medline Epub Ahead of Print, In-Process & Other No
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Pres
Searches
1 exp contraceptive agents/ or exp hormonal contraception/
2 exp contraception/ or fertility control.mp. or (fertiliz* adj3 inhibit*).mp.
3 exp birth control/
4 exp family planning services/
5 desogestrel/ or nor pregnenes/ or progesterone congeners/
6 exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp.
7 dienogest.mp.
8 exp progestin/ or progestin\$.mp. or progestogen.mp.
9 lynestrenol/
10 norethindrone/
11 levonorgestrel/
12 (etynodiol diacetate or ethynodiol diacetate).mp.
13 norgestrel/
14 mestranol.mp. or exp mestranol/
15 exp estradiol/ or estradiol.mp. or oetradiol.mp.
16 (desogestrel or norpregnene\$ or progestins).mp.
17 (progesterone congeners adi2 synthetic).mp.
18 drospirenone.mp.
19 lynestrenol mp
20 norethindrone mp
21 norgestrel mp
22 etonogestrel mp
22 gestodene mp
24 (levonorgestrel or D-norgestrel) mp
25 norgestimate mp
26 dienogest mn
27 contracent* mp
28 birth control mp
20 family planning mp
27 janny planning.mp. 20 Introutoring dovigo mp. or "intro utering dovigo" mp.
21 aug Contracentive Devices Forestal
22 Interactoring contraceptive Devices, Female/
32 Intrauterine system.mp.
33 Intrauterine contraceptive device.mp.
34 iud*.mp. or iucd*.mp.
35 exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depo-
medroxyprogesterone.mp. or medroxyprogesterone.mp.
30 Depo-provera.mp. or depo provera.mp.
18
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xh

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

38	DPMA.mp.		
39	or/1-38		
40	exp sleep/		
41	exp sleep-wake transition disorders/ or exp sleep deprivation/ or exp sleep wake disorders/ or exp dyssomnias/		
42	(fragmented sleep or insufficient sleep syndrome\$).mp.		
43	exp sleep latency/ or exp sleep hygiene/		
44	exp sleep arousal disorder/		
45	exp sleep disorder/		
46	Sleep*.af.		
47	(insomnia\$ or hypersomnia\$).mp. or "disorders of excessive somnolence"/		
48	exp restless legs syndrome/ or restless legs syndrome.mp.		
49	or/40-48 \rightarrow all sleep terms		
50	(comment or letter or editorial or note or erratum or short survey or news or newspaper article or patient education handout or case reports or historical article).pt.		
51	animal/ not human/		
52	or/50-51		
53	(39 and 49) not 52		
51	limit 53 to vr="1970-current"		

Database: Embase 1974 to 2020 August 17

#	Searches			
1	exp contraceptive agents/ or hormonal contraception/			
2	exp contraception/ or fertility control.mp. or fertilization inhibition.mp. or inhibition of fertilization.mp.			
3	exp birth control/			
4	exp family planning services/			
5	desogestrel/ or norpregnenes/ or progesterone congeners/			
6	exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp.			
7	dienogest.mp.			
8	exp progestin/ or progestin\$.mp. or progestogen.mp.			
9	lynestrenol/			
10	norethindrone/			
11	norgestrel/			
12	levonorgestrel/			
13	(etynodiol diacetate or ethynodiol diacetate).mp.			
14	mestranol.mp. or exp mestranol/			
15	exp estradiol/ or estradiol.mp. or oetradiol.mp.			
16	(desogestrel or norpregnene\$ or progestins).mp.			

2					
3	17	(progesterone congeners adj2 synthetic).mp.			
4	18	drospirenone.mp.			
6	19	ynestrenol.mp.			
7	20	orethindrone mp			
8	$\frac{20}{21}$	porgestrel mn			
9	$\frac{21}{22}$	atonogostral mn			
11	22	etonogestier.mp.			
12	23	gestodene.mp.			
13	24	(levonorgestrel or D-norgestrel).mp.			
14	25	norgestimate.mp.			
15 16	26	dienogest.mp.			
17	27	contracept*.mp.			
18	28	Birth Control.mp.			
19	29	Family planning.mp.			
20	30	Intrauterine device.mp. or "intra uterine device".mp.			
∠ı 22	31	exp Contraceptive Devices, Female/			
23	32	Intrauterine system.mp.			
24	33	Intrauterine contracentive device mp			
25	31	iud* mp_or jued* mp			
26 27		ave Medrewwreegesterene/ er Denetmedrewwreegesterene me er dene			
28	35	medroxyprogesterone.mp. or medroxyprogesterone.mp.			
30	36	Depo-provera.mp. or depo provera.mp.			
31	37	(vaginal or hormon* or contraceptive) adi2 (ring or patch or injection).mp.			
32	38	DPMA mp			
33	39	or/1-38			
34	40	exp sleen/			
36	10	exp Sleep, Wake Transition Disorders/ or exp Sleep Deprivation/ or exp Sleep Wake			
37	41	Disorders/ or exp dyssomnias/			
39	42	(fragmented sleep or insufficient sleep syndrome\$).mp.			
40	43	exp sleep latency/ or exp sleep hygiene/			
41	44	exp sleep arousal disorder/			
42	45	sleep*.af.			
43 44	46	(insomnia{ or hypersomnia{) mp_or "disorders of excessive somnolence"/			
45	47	ansonninae of hypersonninae).mp. of ansonaers of excessive sonniotence /			
46	10	avn sleen disorder/			
47	40	exp sieep alsorder/			
48 40	49	or/40-48			
49 50	50	editorial or note or letter erratum or short survey or abstract).pt. or abstract report/ or letter/			
51	51	animal/ not human/			
52 53	51	or/50-51			
55 54	52	or formalal or formalal mp. or woman mp. or woman mp.			
55	55	exp remate/ or remate\$.mp. or women.mp. or woman.mp.			
56	54	(39 and 49 and 53) not 52			
57		22			
28 59		20			

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2
2
2
4
5
6
7
8
0
9
10
11
12
13
14
15
15
16
17
18
19
20
21
∠ I 22
22
23
24
25
26
27
27
28
29
30
31
32
22
22
34
35
36
37
38
30
10
40
41
42
43
44
45
16
40
4/
48
49
50
51
52
52
55
54
55
56
57
58
50

60

1

55	limit 54 to x	/r="19//0_current"
55	μ mm $J = 10$	

Database: Cochrane Central

#	Searches		
1	MeSH descriptor: [Contraceptive Agents] explode all trees		
2	MeSH descriptor: [Hormonal Contraception] explode all trees		
3	MeSH descriptor: [Contraception] explode all trees		
4	Fertility Control		
5	Fertilization inhibition		
6	inhibition of fertilization		
7	MeSH descriptor: [Family Planning Services] explode all trees		
8	MeSH descriptor: [Desogestrel] this term only		
9	MeSH descriptor: [Norpregnenes] this term only		
10	MeSH descriptor: [Progesterone Congeners] this term only		
11	MeSH descriptor: [Ethinyl Estradiol] explode all trees		
12	ethinyl estradiol		
13	ethinylestradiol		
14	dienogest		
15	MeSH descriptor: [Progestins] explode all trees		
16	progestin\$		
17	progestogen		
18	MeSH descriptor: [Lynestrenol] this term only		
19	MeSH descriptor: [Norethindrone] this term only		
20	MeSH descriptor: [Norgestrel] this term only		
21	MeSH descriptor: [Levonorgestrel] this term only		
22	Etynodiol diacetate		
23	mestranol		
24	MeSH descriptor: [Mestranol] explode all trees		
25	MeSH descriptor: [Estradiol] explode all trees		
26	estradiol		
27	oetradiol		
28	(desogestrel or norpregnene\$ or progestins)		
29	progesterone congeners adj2 synthetic		
30	drospirenone		
31	lynestrenol		
32	norethindrone		
33	norgestrel		
34	etonogestrel		
35	gestodene		
36	levonorgestrel		
37	norgestimate		
38	dienogest		
39	contracept*		

1
2
2
1
4
2
6
/
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
23
25
25
20
27 20
20
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
57
52
22
54 57
55
56
5/
58
59
60

40	birth control		
41	family planning		
42	MeSH descriptor: [Intrauterine device] this term only		
43	Intrauterine device		
44	Intrauterine system		
45	Intrauterine contraceptive device		
46	Iud		
47	d-norgestrel		
48	iucd		
49	Depotmedroxyprogesterone		
50	depo-medroxyprogesterone		
51	medroxyprogesterone		
52	Depo-provera		
53	depo provera		
54	DPMA		
55	Vaginal ring/		
56	Ethyndiol diacetate		
57	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or		
	18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or		
	33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or		
	48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56		
58	MeSH descriptor: [Sleep] explode all trees		
59	MeSH descriptor: [Sleep-Wake Transition Disorders] explode all trees		
60	MeSH descriptor: [Sleep Deprivation] explode all trees		
61	MeSH descriptor: [Sleep Wake Disorders] explode all trees		
62	MeSH descriptor: [Dyssomnias] explode all trees		
63	fragmented sleep or insufficient sleep syndrome\$		
64	MeSH descriptor: [Sleep Hygiene] explode all trees		
65	MeSH descriptor: [Sleep Latency] explode all trees		
66	MeSH descriptor: [Sleep Arousal Disorders] explode all trees		
67	sleep*		
68	insomnia\$ or hypersomnia\$		
69	disorders of excessive somnolence		
70	MeSH descriptor: [Restless Legs Syndrome] explode all trees		
71	restless legs syndrome		
72	58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71		
73	(comment or letter or editorial or note or erratum or short survey or news or newspaper		
74	article or patient education handout or case reports or historical article).pt.		
/4	MeSH descriptor: [Animals] explode all trees		
15	MeSH descriptor: [Humans] explode all trees		
/6	/ 3 and /4 not / 3		
70	(5/ and /2) not /6		
/8	IImit // to yr="19/0-current"		

REFERENCES

- United Nations. Contraceptive Use by Method 2019: Data Booklet [Internet]. UN; 2019 [cited 2020 Jul 20]. Available from: <u>https://www.un-ilibrary.org/population-anddemography/contraceptive-use-by-method-2019_1bd58a10-en</u>
- van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception [Internet]. 2005 Sep;72(3)[cited 2021 March 1]:168–74. Available from: https://pubmed.ncbi.nlm.nih.gov/16102549/
- Dean, Gillian; Schwarz, Eleanor Bimla (2011). "Intrauterine contraceptives (IUCs)". In Hatcher, Robert A.; Trussell, James; Nelson, Anita L.; Cates, Willard Jr.; Kowal, Deborah; Policar, Michael S. (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 147–191.
- Lancel M, Faulhaber J, Schiffelholz T, Romeo E, Di Michele F, Holsboer F, et al. Allopregnanolone affects sleep in a benzodiazepine-like fashion. J Pharmacol Exp Ther [Internet]. 1997 Sep [cited 2020 Jul 20] ;282(3):1213–8. Available from: <u>https://pubmed.ncbi.nlm.nih.gov/9316828/</u>
- Allada R, Cirelli C, Sehgal A. Molecular Mechanisms of Sleep Homeostasis in Flies and Mammals. Cold Spring Harb Perspect Biol [Internet]. 2017 Aug 1[cited 2020 Jul 20];9(8). Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538413/Schwartz MD, Mong JA.

- Estradiol modulates recovery of REM sleep in a time-of-day-dependent manner. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2013 May 15;305(3):R271–80.
- Bezerra AG, Andersen ML, Pires GN, Tufik S, Hachul H. Effects of hormonal contraceptives on sleep - A possible treatment for insomnia in premenopausal women. Sleep Sci [Internet]. 2018 Jun [cited 2020 Jul 20];11(3):129–36. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201525/

BMJ Open

- 8. Léger D, Bayon V. Societal costs of insomnia. Sleep Med Rev. 2010;14(6):379-89.
- Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16(5):873-97; discussion 854.
- Gourineni R. Prognosis and complications. In: Attarian HP, ed. Clinical Handbook of Insomnia. 3rd ed. New York: Springer; 2017. p. 59-73.
- Kessler, R.C., Berglund, P.A., Coulouvrat, C., Hajak, G., Roth, T., Shahly, V., et al. (2011). <u>Insomnia and the performance of US workers: results from the America insomnia</u> <u>survey</u>. *Sleep*; 34(9): 1161–1171.
- 12. Ohayon, M.M., O'Hara, R., Vitiello, M.V. (2012). Epidemiology of restless legs syndrome: a synthesis of the literature. *Sleep Medicine Reviews*; 16(4): 283–295.
- Wimms, A., Woehrle, H., Ketheeswaran, S., Ramanan, D., Armitstead, J. (2016). <u>Obstructive Sleep Apnea in Women: Specific Issues and Interventions</u>. *Biomed Research International; 2016: 1764837.*
- 14. Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2020 Sep 28]. Available from: <u>http://www.ncbi.nlm.nih.gov/books/NBK279054/</u>
- Baker FC, Lee KA. Menstrual Cycle Effects on Sleep. Sleep Med Clin [Internet]. 2018 Sep[cited 2021 Mar 1];13(3):283–94.
- 16. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol [Internet]. 1999 Nov [cited 2020 Jul 20] ;181(5 Pt 1):1263–9. Available from: https://pubmed.ncbi.nlm.nih.gov/10561657/
- 17. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review. Cancer Epidemiol Biomarkers Prev [Internet]. 2013 Nov 1 [cited 2020 Jul 20];22(11):1931–43. Available from: https://pubmed.ncbi.nlm.nih.gov/24014598/
- 18. Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb

Haemost [Internet]. 1997 Jul [cited 2020 Jul 20] ;78(1):327–33. Available from: https://pubmed.ncbi.nlm.nih.gov/9198174/

- 19. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The Risk of Deep Venous Thrombosis Associated With Injectable Depot–Medroxyprogesterone Acetate Contraceptives or a Levonorgestrel Intrauterine Device. Arteriosclerosis, Thrombosis, and Vascular Biology [Internet]. 2010 Nov 1 [cited 2021 Jun 23];30(11):2297–300. Available from: https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.110.211482
- 20. LeBlanc ES, Laws A. Benefits and Risks of Third-Generation Oral Contraceptives. J Gen Intern Med [Internet]. 1999 Oct [cited 2020 Jul 20];14(10):625–32. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1496751/
- 21. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study, American Journal of Obstetrics and Gynecology [Internet]. 2017 Jun 1 [cited 2020 Jul 20] ;216(6):580.e1-580.e9. Available from: https://pubmed.ncbi.nlm.nih.gov/28188769/
- 22. Guida M, Rega A, Vivone I, Saccone G, Sarno L, Di Carlo C, et al. Variations in sleep associated with different types of hormonal contraceptives. Gynecol Endocrinol [Internet]. 2020 Feb [cited 2020 Jul 20] ;36(2):166–70. Available from: https://pubmed.ncbi.nlm.nih.gov/31311352/
- 23. Hachul H, Andersen ML, Bittencourt L, Santos-Silva R, Tufik S. A population-based survey on the influence of the menstrual cycle and the use of hormonal contraceptives on sleep patterns in São Paulo, Brazil. Int J Gynaecol Obstet [Internet]. 2013 Feb[cited 2020] Jul 20];120(2):137–40. Available from:

https://www.sciencedirect.com/science/article/abs/pii/S0020729212005619

- 24. Lundin C, Danielsson KG, Bixo M, Moby L, Bengtsdotter H, Jawad I, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology [Internet]. 2017[cited 2020 Jul 20];76:135-43. Available from: https://pubmed.ncbi.nlm.nih.gov/27923181/
- 25. Bezerra AG, Andersen ML, Pires GN, Banzoli CV, Polesel DN, Tufik S, et al. Hormonal contraceptive use and subjective sleep reports in women: An online survey. J Sleep Res

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.	Enseignement Superieur (ABES) .	AJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de l
--	---------------------------------	--

BMJ Open
[Internet]. 2020 Jan 27 [cited 2020 Jul 20] ;e12983. Available from:
https://pubmed.ncbi.nlm.nih.gov/31989746/
26. Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., &
Stewart, L. A. (2015). Preferred reporting items for systematic review and meta-analysis
protocols (PRISMA-P) 2015 statement. Systematic reviews, 4(1), 1.
27. Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A
new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol.
2016;69:225-34.
28. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-
2010, and changes in patterns of use since 1995. Natl Health Stat Report [Internet].2012
Oct 18;(60):1–25.Available from:
https://pubmed.ncbi.nlm.nih.gov/24988814/#:~:text=Use%20of%20intrauterine%20devic
es%20as,current%2C%20most%20effective%20contraceptive%20method.
29. Rao U, Hammen CL, Poland RE. Ethnic differences in electroencephalographic sleep
patterns in adolescents. Asian J Psychiatr [Internet]. 2009 Mar 1;2(1):17–24. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786078/
30. Grandner MA, Patel NP, Gehrman PR, Xie D, Sha D, Weaver T, et al. Who Gets the Best
Sleep? Ethnic and Socioeconomic Factors Related to Sleep Complaints. Sleep Med
[Internet]. 2010 May;11(5):470–8. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861987/
31. Nassaralla CL, Stanford JB, Daly KD, Schneider M, Schliep KC, Fehring RJ.
Characteristics of the Menstrual Cycle After Discontinuation of Oral Contraceptives. J
Womens Health (Larchmt) [Internet]. 2011 Feb 1 [cited 2021 Jun 24];20(2):169-77.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643763/
32. Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on
mood: a critical review. Eur J Contracept Reprod Health Care. 2016 Oct;21(5):347-55.
33. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep
Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res
[Internet]. 1989 May [cited 2020 Jul 20] ;28(2):193-213. Available from:
https://pubmed.ncbi.nlm.nih.gov/2748771/

34. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep [Internet]. 1991 Dec [cited 2020 Jul 20];14(6):540–5. Available from: https://pubmed.ncbi.nlm.nih.gov/1798888/

- 35. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. Journal of Psychosomatic Research [Internet].
 2000[cited 2020 July 20] ;48:555–60. Available from: https://pubmed.ncbi.nlm.nih.gov/11033374/
- 36. The Insomnia Severity Index: Psychometric Indicators to Detect Insomnia Cases and Evaluate Treatment Response [Internet]. [cited 2020 Jul 20]. Available from: <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079939/</u>
- 37. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric [Internet]. 2005 Aug [cited 2021 March 1];8 Suppl 1:3–63. Available from: https://pubmed.ncbi.nlm.nih.gov/16112947/
- 38. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 Aug 28 [cited 2020 Sep 28];366. Available from: <u>https://www.bmj.com/content/366/bmj.14898</u>
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 [cited 2020 Jul 20]; 28;366:14898. Available from: <u>https://pubmed.ncbi.nlm.nih.gov/31462531/</u>
- 40. Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225-34.
- 41. Schünemann HJ, Brożek J, Guyatt G, Oxman A. GRADE handbook [Internet]. GRADE Handbook. 2013 [cited 2020 Sep 28]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html
- 42. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003 Sep 4;327(7414):557–60.
- 43. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.

BMJ Open

- 44. Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1998.
 - 45. Chaimani A, Caldwell DM, Li T. Chapter 11: Undertaking network meta-analyses: Higgins JPT, Thomas J, Chandler J, et al., Cochrane Handbook for Systematic Reviews of Interventions. version 6.0 (updated July 2019) Cochrane, 2019
 - 46. Caldwell DM, Welton NJ. Approaches for synthesising complex mental health interventions in meta-analysis. Evid Based Ment Health. 2016;19(1):16–21.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

 Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page
		Reporting Item	Number
Title			y
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	1
Update	<u>#1b</u>	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	<u>#2</u>	If registered, provide the name of the registry (such as PROSPERO) and registration number	300
Authors			
Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the guarantor of the review	17
	For pe	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Amenuments			
	<u>#4</u>	If the protocol represents an amendment of a previously completed or	n/a
		published protocol, identify as such and list changes; otherwise, state	
		plan for documenting important protocol amendments	
Support			
Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	17
Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	n/a
Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any,	17
funder		in developing the protocol	
Introduction			
Rationale	#6	Describe the rationale for the review in the context of what is already	5-7
		known	
Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review will	7
		address with reference to participants, interventions, comparators, and	
		outcomes (PICO)	
Methods			
Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study design, setting,	8-12
		time frame) and report characteristics (such as years considered,	
		language, publication status) to be used as criteria for eligibility for	
		the review	
Information sources	#9	Describe all intended information sources (such as electronic	7-8
internation sources	<u></u>	databases, contact with study authors, trial registers or other grey	7 0
		literature sources) with planned dates of coverage	
Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one electronic	18-23
		database, including planned limits, such that it could be repeated	
Study records - data	<u>#11a</u>	Describe the mechanism(s) that will be used to manage records and	12-13
management		data throughout the review	
Study records -	<u>#11b</u>	State the process that will be used for selecting studies (such as two	12-13
selection process		independent reviewers) through each phase of the review (that is,	
		screening, eligibility and inclusion in meta-analysis)	
Study records - data	#11c	Describe planned method of extracting data from reports (such as	12-13
stady records data	<u></u>	2 course prunied method of extracting data noni reports (such ds	14 13

	BMJ Open Page 32 of				
1 2 3 4 5 6 7 8 9 10 11 2 13 14 15 16 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 14 15 16 7 8 9 20 21 22 3 24 25 26 27 8 9 30 31 22 33 45 36 37 8 9 0 11 22 32 4 5 6 7 8 9 0 11 22 32 4 5 6 7 8 9 0 11 22 32 4 5 6 7 8 9 0 11 22 32 4 5 6 7 8 9 0 31 32 33 45 36 37 8 9 0 11 22 32 4 5 6 7 8 9 0 11 22 32 4 5 6 7 8 9 0 31 32 33 45 36 37 8 9 0 11 22 32 4 5 6 6 7 8 9 0 31 32 33 44 5 6 7 7 8 9 0 1 22 33 44 5 6 7 7 8 9 0 31 22 33 44 5 6 7 7 8 9 0 31 32 33 44 5 6 7 7 8 9 0 1 22 33 44 5 6 7 7 8 9 0 1 22 33 44 5 6 7 7 8 9 0 1 22 3 3 4 5 6 6 7 8 9 0 1 22 3 3 4 5 6 6 7 8 9 0 1 22 3 3 4 5 5 6 7 7 8 9 0 1 2 3 3 4 5 5 6 7 7 8 9 0 1 2 3 3 4 5 5 6 7 7 8 9 0 1 2 3 3 4 5 5 6 7 7 8 9 0 1 2 3 3 4 5 5 6 7 7 8 9 0 1 2 3 4 5 5 6 7 7 8 9 0 1 2 5 3 4 5 5 6 7 7 8 9 9 0 1 2 5 5 7 8 9 9 0 1 2 5 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 5 7 8 9 9 0 1 2 5 7 8 9 9 0 1 5 7 8 9 9 9 9 0 1 2 5 7 8 9 9 0 1 5 7 8 9 1 5 7 8 9 9 1 5 7 8 9 9 0 1 5 1 5 7 8 9 1 5 9 1 1 2 1 5 1 5 1 5 7 8 9 10 1 5 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	collection process		piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators		BMJ Open:
	Data items	<u>#12</u>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	12-	13 first published
	Outcomes and prioritization	<u>#13</u>	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	12-	13 Protec
	Risk of bias in individual studies	<u>#14</u>	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis		ted by copyrig
	Data synthesis	<u>#15a</u>	Describe criteria under which study data will be quantitatively synthesised	14-	0-045819 o 15ncludir
	Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall's τ)	14-	n 8 October 2021. ש Enseignemei ק for uses related t
	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	14-	nt Superieu text and o
	Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the type of summary planned	14-	I from http: Ir (ABES) data mining
	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)		g, Al trainii
	Confidence in cumulative evidence	<u>#17</u>	Describe how the strength of the body of evidence will be assessed (such as GRADE)		.bmj.com/ on ر ng, and similar ا
	The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 29. June 2021 using https://www.goodreports.org/, a tool made by the <u>EQUATOR Network</u> in collaboration with <u>Penelope.ai</u> For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml				

BMJ Open

The Relationship between Hormonal Contraceptives and Sleep among Women of Reproductive Age: A Systematic Review Protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-045819.R3
Article Type:	Protocol
Date Submitted by the Author:	15-Sep-2021
Complete List of Authors:	Ma, Jinhui; McMaster University, Department of Health Research Methods, Evidence, and Impact Cheng, Megan; McMaster University Faculty of Health Sciences, Thabane, Lehana; McMaster University, Department of Health Research Methodology, Evidence, and Impact Ma, Caihong; Peking University Third Hospital, Zhang, Ning; Beijing Tiantan Hospital, Capital Medical University, Department of Neuropsychiatry and Behavioral Neurology ; Capital Medical University, Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Wang, Qi; McMaster University, Department of Health Research Methods, Evidence, and Impact Kim, Hyunwoo; McMaster University, Department of Health Research Methods, Evidence, and Impact Reza, Hameed; McMaster University, Faculty of Science Wang, Chunxue; Beijing Tiantan Hospital, Capital Medical University; Capital Medical University, SInstitute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Wang, Chunxue; Beijing Tiantan Hospital, Capital Medical University; Capital Medical University, SInstitute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders Yao, Xiaomei; McMaster University, Department of Health Research Methods, Evidence and Impact; McMaster University, Department of Health Research Methods, Evidence and Impact; McMaster University, Department of Oncology
Primary Subject Heading :	Sexual health
Secondary Subject Heading:	Public health, Research methods
Keywords:	REPRODUCTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



The Relationship between Hormonal Contraceptives and Sleep among Women of Reproductive Age: A Systematic Review Protocol

Jinhui Ma¹, Megan Cheng², Lehana Thabane¹, Caihong Ma³, Ning Zhang⁴, Qi Wang¹, Hyunwoo Kim¹, Hameed Reza⁵, Chunxue Wang⁴, Xiaomei Yao^{1,6}

¹Department of Health Research Methods, Evidence, and Impact, McMaster University,

Hamilton, Ontario, Canada

²Faculty of Health Science, McMaster University, Hamilton, Ontario, Canada

³Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking

University Third Hospital, Beijing, China

⁴Department of Neuropsychiatry and Behavioral Neurology, Beijing Tiantan Hospital, Capital

Medical University, Beijing, China

⁵Faculty of Science, McMaster University, Hamilton, Ontario, Canada

⁶Center for Clinical Practice Guideline Conduction and Evaluation, Children's Hospital of Fudan

University, Shanghai, China

Corresponding:

Xiaomei Yao: 711 Concession Street, Hamilton, L8V 1C3, ON, Canada, Tel: +1-9055274322

ext. 42824, E-mail: yaoxia@mcmaster.ca

Chunxue Wang: No. 119 South Fourth Ring West Road, Fengtai District, Beijing 100070, P.R.

China ,Tel: +01186-13701193710, E-mail: snowsen@126.com

ABSTRACT

Introduction The etiology of sleep disruptions is unknown but hormonal fluctuations during the menstrual cycle, pregnancy, and menopause have been shown to potentially affect how well a woman sleeps. The aim of this systematic review is to investigate whether hormonal contraceptives are associated with a decreased quality of sleep and increased sleep duration in women of reproductive age.

Methods This review will analyze data from randomized controlled trials or non-randomized comparative studies investigating the association between hormonal contraceptives and sleep outcomes among women of reproductive age. Reviews addressing the same research question with similar eligibility criteria will be included. A literature search will be performed using the MEDLINE, EMBASE and Cochrane CENTRAL databases from inception to March 7, 2021. The Cochrane Collaboration's Risk of Bias for Randomised Trials (RoB 2.0) and The Cochrane Risk of Bias for Non-randomized studies – of Interventions (ROBINS-1 tool) will be used to assess risk of bias for each outcome in eligible studies. Two reviewers will independently assess eligibility of studies, risk of bias and extract the data. All extracted data will be presented in tables and narrative form. For sleep measures investigated by two or more studies with low heterogeneity, we will conduct random-effects meta-analysis to estimate the magnitude of the overall effect of hormonal contraceptives. If studies included in this systematic review form a connected network, a network meta-analysis will be conducted to estimate the comparative effect of different contraceptives. The GRADE approach will be used to summarise the quality of evidence. Our protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015) guidelines.

Ethics and dissemination: Ethics approval is not required as data is sourced from previously

reported studies. The findings of this review will be published in a peer-reviewed journal and

presented at relevant conferences.

Keywords: hormonal contraceptive, oral contraceptive, contraception, sleep quality, sleep duration **PROSPERO registration number:** CRD42020199958.

Article Summary

Strengths and Limitations of this study:

- This systematic review on the association between hormonal contraceptive use and sleep is based on a robust, librarian consulted search strategy.
- The literature review, data extraction, and risk of bias assessment are performed by two independent reviewers to mitigate bias.
- The risk of bias of each outcome from included papers will be assessed with the appropriate tool.
- Papers in languages other than English are not included, leading to potential for language bias.

Word Count: 3703

INTRODUCTION

Worldwide, there are around 1.9 billion women of reproductive age. Hormonal contraceptives including oral contraceptives (OC), vaginal ring, contraceptive skin patches, implants, injections, and hormonal intrauterine contraceptive devices (IUDs), are widely used around the world in women of reproductive age to avoid unintentional pregnancy.¹ Of the 842 million women using modern forms of contraception, 43% are using hormonal contraceptives. The overall number of users of hormonal contraceptives is increasing annually. ¹ One hundred and fifty-one million women use OCs with usage varying by region.¹ Other hormonal contraceptives such as implants, vaginal rings, and intrauterine devices have been widely adopted as well and used by over 256 million women in the world.¹ These hormonal contraceptives have different dosage, formulation, mechanism of action, and applicable groups compared to OCs.² Unlike OCs which are taken consistently and provide a stable dosage of the estrogen and progestin components, other hormonal contraceptives have the potential to provide lower dose of progestin and estrogen. It has been shown that hormonal IUDs release levonorgestrel directly into the uterus, only a small amount is absorbed into the rest of the body, thus its effects are mostly paracrine rather than systemic.³

Progesterone, a primary component in hormonal contraceptives, is an agonist of gammaaminobutyric acid (GABA) receptors through a metabolite, allopregnanolone. ⁴GABA is a crucial molecule in sleep promotion – most sleep-promoting neurons are sensitive to GABA. ⁵ Common sleep medications, such as benzodiazepines have been shown to positively modulate GABA signalling.⁵ The potency of progestin is comparable to that of benzodiazepines and has similar agonistic effects. Changes in electroencephalogram activity seen with progesterone administration

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

are similar to those evoked by benzodiazepines.⁴ Studies in rat models have shown that administration of exogenous progesterone leads to dose-dependent decreased sleep latency and wakefulness.⁴ The mechanism behind the effect of estrogen on sleep is not well elucidated but rat studies have shown that administration of estrogen promotes sleep during the sleep period and reduces sleep during the wakefulness period.⁶ The overall effect on sleep is likely caused by a combination of both estrogen and progesterone, although the magnitude of their contribution to sleep changes is unknown.⁷

High quality sleep is as essential as regular exercise and eating a balanced diet for maintenance of optimal health and well-being. Severe sleeping problems, such as insomnia, are important matters from both a public health perspective and an individual level. Insomnia is associated with depression, anxiety, substance abuse, cognitive impairment, metabolic disorders (e.g., diabetes, dyslipidemia, and obesity) and cardiovascular diseases.⁸⁻¹⁰ Women are more likely than men to have sleep problems including insomnia and restless leg syndrome. The exact etiology of these sleep disruptions is unknown but hormonal fluctuations during the menstrual cycle. pregnancy, and menopause have been shown to potentially affect how well a woman sleeps.¹¹⁻¹³ During ovulation, there is a surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which leads to a decrease in estrogen concentration and an increase in progesterone.¹⁴ During the luteal phase, progesterone concentrations increase and estrogen levels are high up to the mid-phase. Starting from the mid-luteal phase, both estrogen and progesterone levels decrease.¹⁴ Sleep disturbances are most commonly reported at the end of the luteal phase and early follicular phase.¹⁵ OCs are taken each day for 21 days, providing a constant, exogenous source of estrogen and progesterone, preventing the release of FSH and LH and thus the production of a

BMJ Open

follicle or ovulation.¹⁶ Therefore, hormonal contraceptives may affect women's sleep-wake cycle and cause physiological changes that lead to sleep disturbance.

Unlike other commonly prescribed drugs, hormonal contraceptives are used by healthy women for long periods of time. Safety trials of hormonal contraceptives have focussed largely on breast cancer and venous thromboembolism risk. ¹⁷⁻¹⁹ Despite decreases in estrogen concentration with later OC generations, its use has been shown to be associated with an increased risk of developing breast cancer and venous thromboembolism.²⁰ A 2017 cohort study found OC intake was associated with a reduced risk of colorectal, endometrial and ovarian cancers and increased risk of cervical and breast cancer.²¹ Studies in women have varied findings on the association between hormonal contraceptive use and sleep quality and duration. Differences in methodology, including the formulation of contraceptives taken, stratification of formulations, measurements of sleep, or the phase of the menstrual cycle of naturally cycling women used as comparison may explain the different findings between studies. For instance, a pilot study published in 2020 by Guida *et al* found significantly increased sleep duration for users of oral progestins, oral gestodene and 13.5 mg levonorgestrel intrauterine systems, compared with naturally cycling women (women not currently using any hormonal contraceptive), and decreased sleep latency and better sleep quality for users of depot-administered contraceptives.²² However, a polysomnography study published in 2012 by Hachul et al found decreased sleep latency in women using OC and no difference in overall sleep quality.²³ A randomized control trial by Lundin et al found no significant sleep related results, while a cross sectional analysis by Bezerra *et al* found that hormonal contraceptive users had worse sleep quality compared with their naturally cycling counterparts.²⁴⁻

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Given the high prevalence of hormonal contraceptive use among women of reproductive age and the relationship between hormonal contraceptive use and sleep varying in both magnitude and direction in the current literature, there is an urgent need to provide women with accurate, evidence-based information to inform their use of hormonal contraception.²²⁻²⁵ Hence, the objective of this systematic review is to compile and elucidate the association between hormonal contraceptive use and sleep (including the quality of sleep, sleep disorders, and duration of sleep). Our hypothesis is hormonal contraceptives are associated with a decreased quality of sleep and increased sleep duration in women of reproductive age. Findings from this review will provide insights to women choosing between different methods and formulations, while also inform the development of new progestins for future generations of hormonal contraceptives. The systematic review protocol was registered at the website of the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD42020199958).

METHODS

Our protocol follows the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015) guidelines.²⁶

Literature search

We developed a comprehensive search strategy with input from a research librarian at McMaster University (tables 1-3). The systematic search for existing relevant systematic review and original studies will be conducted in the Ovid MEDLINE and Embase (Excerpta Medica dataBASE) electronic databases, and the Cochrane Library (including Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials), from inception to March 7, 2020. Search terms will cover all words related to birth control, ingredients of oral

BMJ Open

contraceptives, hormonal contraceptives, menstrual cycle, and sleep. We will limit the search to studies or systematic reviews published from 1970 to present to ensure that we include all published studies or reviews on hormonal contraceptives, excluding first generation oral contraceptives which had been discontinued after 1970s. For sleep outcome measures, we will search sleep terms in multi-purpose fields besides the title and abstract in case sleep is investigated as a secondary outcome and therefore not reported in the abstract. The comprehensive search strategies for each database are presented in Tables 1-3. The reference lists of all included studies will be checked to identify additional potentially eligible studies.

Study Selection and Screening

Systematic screening of the studies will be first conducted at the title and abstract level, and then at the full-text level to determine if a study meets eligibility criteria by two independent reviewers. Any potential conflicts between the reviewers will be resolved through discussion. If discrepancies in judgment remain after discussion, a third-party reviewer will be consulted to resolve the conflict and provide a final decision.

Eligibility criteria

(1) Study Characteristics

Existing systematic reviews will be included if they (i) address the same research question with similar inclusion and exclusion criteria as ours; and (ii) have a low risk of bias in study eligibility criteria, identification and selection of studies, data collection and study appraisal, and synthesis and findings assessed using the Risk of Bias in Systematic Reviews (ROBIS) tool.²⁷

For original studies, we will include (i) randomized controlled trials, and non-randomized comparative studies that take into account the effect of potential confounders (e.g., age, race, and socioeconomic status)²⁸⁻³⁰ using methods such as multivariable analysis, propensity-score

matching, or showing no statistically significant differences in baseline characteristics between participants in comparison groups; (ii) studies on human participants; and (iii) studies which investigate the association between hormonal contraceptive use and sleep-related outcomes, either as the primary or secondary objective.

(2) Participants

Participants or subgroups of participants are females between 15 and 49 years old.

(3) Exposure

Participants who take second generation or more recent OC or other hormonal contraceptives containing both progesterone and estrogen or progesterone only, regardless of its brand, dose, and frequency, to avoid pregnancy, as long as their hormonal contraceptive use pattern is sustained for at least three months by the time sleep outcomes are assessed. The first three months of hormonal contraception use or discontinuation of hormonal contraception are excluded to account for altered menstruation that occurs following discontinuation of hormonal contraception.³¹⁻³²

(4) Comparator

Included studies must have comparison groups of women who are using (i) non-hormonal contraceptives; (ii) naturally cycling (i.e., not use any contraceptive methods) or placebo; (iii) same agent as the exposure but in different dose, frequency, and duration; and (iv) second generation or more recent OC or other hormonal contraceptives different from the exposure. Since recent usage or cessation of hormonal contraceptive use may cause hormonal oscillations, we will only include studies with participants keeping their contraceptive use pattern (either using different hormonal contraceptives from the exposure or placebo, or not using any hormonal contraceptive) for at least three months by the time sleep outcomes are assessed.

BMJ Open

(5) Outcomes

We are interested in any sleep-related outcomes assessed at any time points after keeping their contraceptive use pattern for at least three months. A variety of sleep measurements for sleep quality, sleep duration, and sleep disorder will be included in this systematic review. The sleep measurements can be questionnaires based on Likert Scale items listed below but not limited to these tools:

(i) The Pittsburgh Sleep Quality Index (PSQI). ³³ It measures seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction over the last four weeks. The PSQI is a subjective measure of sleep. Subjects self-rate each of the seven domains of sleep from 0 to 3, where 3 represents the negative extreme on the Likert Scale. A subject with a global sum of 5 or greater is considered as a poor sleeper. Studies reported sleep quality in any of the above seven domains during and after taking hormonal contraceptives will be included in the review.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

- (ii) The Epworth Sleepiness Scale (ESS) is a self-administered test used to assess daytime sleepiness.³⁴ It consists of 8 questions with different scenarios and a scale from 0-3 where subjects would indicate how likely they are to fall asleep in that situation. The scores are summed for a total score between 0 and 24. ³⁴ Studies reporting sleepiness with any of the 8 questions during and after taking hormonal contraceptives will be included in the review.
- (iii) The Athens Insomnia Scale (AIS), which is also a self-administered psychometric instrument designed for quantifying sleep difficulty.³⁵ The AIS consists of eight items: sleep induction (i.e., time to fall asleep after turning-off the lights), night awakenings,

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

> final awakening earlier than desired, total sleep duration, overall quality of sleep, sense of well-being during the day, functioning (physical and mental) during the day, and sleepiness during the day. Each item is rated from 0 to 3 with higher scores indicating more impaired sleep. The total score ranges from 0 to 24 and a total score of 6 or more is considered as insomnia. Studies which report any or all of the above eight insomniarelated items during and after taking hormonal contraceptives will be included in the review.

(iv) The Insomnia Severity Index (ISI), a self-administered questionnaire used to assess insomnia.³⁶ The ISI consists has a one month recall period and assesses 7 domains: severity of sleep onset, sleep maintenance, difficultly waking up in the morning, sleep dissatisfaction, interference of sleep with daytime functioning, noticeability of sleep problems by others, and distress caused by sleep difficulties. Each domain is rated on a scale from 0 to 4 with higher scores indicating more problematic sleep. The score is summed forming a total score between 0 and 28, with a score of 8 and above indicative of insomnia.³⁶ Studies reporting any domains from the ISI during and after taking hormonal contraceptives will be included in the review.

We will also include continuous measures of sleep quality and disorder. These measures include: (i) total amount of sleep obtained, either during nocturnal sleep episode or across the 24hour period; (ii) sleep latency, i.e., how long it takes the participant to fall asleep; (iii) how many times the participant wakes up; (iv) how many minutes the participant is awake during the night; (v) sleep efficiency, i.e., what percentage of time spent in bed the participant is actually asleep. The total sleep time is equal to the total amount of time spent in bed (in minutes) minus the sum of time it takes to fall asleep, and the time spent awake throughout the night. The percentage is
Page 13 of 29

BMJ Open

calculated as the total sleep time divided by total time in bed. Given we will only include studies with participants keeping their contraceptive use pattern for at least three months, the sleep outcomes from the eligible studies will be summarized after participants keeping their contraceptive use pattern for at least three months as well.

Exclusion criteria

The following studies will be excluded from this systematic review: (1) studies only recruited patients with specific comorbidities or conditions, such as hormonal disorder, acne, perimenopause, postmenopause, dysmenorrhea, depression etc., since these conditions may be associated with sleep problems and will not allow us to elucidate the association between hormonal contraceptives and sleep; (2) studies investigating the first-generation OC since it is not available in the market anymore due to severe side effects; (3) studies investigating emergency contraception; and (4) studies in languages other than English. We will exclude emergency contraception from this review as the hormonal effect of the emergency contraception is significantly different from long-acting contraception. The half-life of oral leovnoregestrel is around 24-32 hours, which is not significant when considering long-term effect on sleep.³⁷

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Data abstraction

A standard form will be developed to extract data from the included studies. From each article, the author, study design, study population, publication year, journal, participant demographics, hormonal contraceptive used, intervention details, comparison groups, sleep outcomes, and the association between hormonal contraceptive use and sleep will be extracted. Additionally, any mean values, standard deviation and confidence intervals, and all information

needed for appraisal of internal validity will be extracted. This will be done in a standardized data extraction form by two reviewers independently. When consensus is not reached, a third researcher will be consulted to reach the final decision. Data will be presented in narrative form and summary tables.

Risk of bias assessment

For randomized controlled trials, the risk of bias in each included study for each outcome will be evaluated independently by two reviewers, using the Cochrane Collaboration Risk of Bias in randomized trials (RoB 2.0 tool).³⁸ Studies will be assessed from 5 domains: bias from randomisation, bias from deviates from intended interventions, bias due to missing data, bias in outcome measurement and bias in the selection of the reported result.³⁸ An overall rating of low bias, some concerns about bias, or high bias will be given depending on the result of assessment. The Cochrane Risk of Bias in Non-randomized studies – of Interventions (ROBINS-1 tool) will be used to assess the risk of bias for each outcome in non-randomized comparative studies.³⁹ Studies will be assessed from 7 domains: bias due to confounding, bias in selection of participants into the study, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement outcomes, and bias in selection of the reported result. Risk of Bias in Systematic Reviews (ROBIS) tool will be used to assess the risk of bias for the eligible systematic reviews.⁴⁰ Reviews will be assessed from four domains: study eligibility criteria, identification and selection of studies, data collection and study appraisal, and synthesis and findings. We will also assess the overall risk of bias in the interpretation of review findings and whether this considered limitations identified in any of the above 4 domains.

Grading the strength of evidence

BMJ Open

The certainty of the evidence per outcome for each comparison will be assessed from five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach and be classified into four levels of evidence (high, moderate, low or very low).⁴¹

Data synthesis

All data extracted will be presented in both narrative form and in summary tables. If data are missing, the study authors will be contacted to attempt to obtain the data. For sleep measures investigated by two or more studies, if there is no clinical heterogeneity (e.g., different age or intervention) and methodological heterogeneity (e.g., different measurement tools), statistical heterogeneity will be assessed using forest plot visually, the chi-square test of homogeneity (p value < 0.05), and quantified using the Higgins' I² statistic with 25%, 50% and 75% representing low, medium, and high heterogeneity, respectively.⁴² The presence of publication bias will be evaluated using a funnel plot and the Duval and Tweedie's trim and fill method.⁴³

We will use frequentist approach to estimate the overall effect of hormonal contraceptives on sleep. For binary outcome measures, we will express the results of each study as a risk ratio (RR) and its 95% confidence interval (CI). We will perform meta-analyses of pooling the RRs with 95% CIs of studies using a random-effects model, because of anticipated heterogeneity of hormonal contraceptives, study designs, and participants. For continuous outcome measures, standardized mean differences (SMDs) will be used for the final assessment from individual studies due to the likely variability in the measuring scales. The SMD will be categorized as small, medium, and large based on the thresholds 0.2, 0.5 and 0.8, respectively, as suggested by Cohen's.⁴⁴ The 95% CI will be used to represent the deviation from the point estimate for both the individual studies and the pooled estimate. Random-effects meta-analysis will be used to obtain

Page 16 of 29

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

> the pooled estimates. If sleep outcomes are measured at multiple time points in a study, the measure done at the similar time point as the other studies will be used in the primary meta-analysis. The outcome measured at other time points will be considered in the subgroup analysis by duration of hormonal contraceptives.

> We will run subgroup analyses by hormonal method of contraception (implant, IUD, injections, pills, vaginal rings, or skin patches), agent (progesterone and estrogen combined or progesterone only), dose, and duration of contraceptives. We will run sensitivity analyses to assess whether our conclusions will be robust if excluding studies with high risk of bias and nonrandomized comparative studies. As long as studies included in the systematic review form a connected network, a network meta-analysis using both direct and indirect evidence will be conducted to estimate the comparative harm of different contraceptives.⁴⁵⁻⁴⁶ Results from the network meta-analysis will allow us to summarize and interpret a wider picture of the evidence for the putative effect of hormonal contraceptives on sleep. We will conduct data analysis using the Cochrane Collaboration Review Manager statistical software (Version 5.4.1) (http://ims.cochrane.org/RevMan).

Patient and Public Involvement

There is no patient or public involvement in this study.

Ethics and Dissemination

Ethical approval is not required for this protocol nor the subsequent review, as this review only consists of an analysis of previously published works. The findings of this review will be published in a peer-reviewed journal and disseminated in conferences related to this topic. All amendments to this protocol will be documented in the publication of the review.

DISCUSSION

Strengths and limitations

This systematic review will be the first to provide quantitative estimates of the association between hormonal contraceptive use and sleep outcomes in healthy women. Our systematic review methodology includes explicit eligibility criteria created in consultation with research librarians, and the usage of tested, standardized abstraction forms. We will calibrate our review methods throughout the review process for optimal consistency among reviewers. The GRADE approach will be applied to aggregate data, the PRISMA-P reporting checklist is followed to draft this systematic review protocol, and the PRISMA reporting checklist will be followed to draft this systematic review later. The κ statistic will be reported to identify issues with reproducibility. Our review will encompass a wide range of hormonal contraceptive formulations and sleep outcome measurements. We anticipate limitations with regard to publication bias and recall bias as the majority of studies employ self-administered tools to assess sleep quality and duration.

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Study implications

Sleep quality is a crucial outcome that affect overall life quality in women of reproductive age and may indicate risk of developing comorbid conditions. The relationship between hormonal contraceptive use and sleep quality, duration and disorder have been reported inconsistently in the current literature. Hormonal contraceptives have been more and more widely accepted by women. However, no study has attempted to provide systematic evidence on the association between hormonal contraceptive use and sleep. Our systematic review will elucidate the association between hormonal contraceptive use and sleep quality. Moreover, it will contribute evidence that

BMJ Open

will support the improvement of guidelines for taking hormonal contraceptive in healthy women and promote awareness of safety for taking hormonal contraceptive.

It is challenging to design, conduct, and analyze original studies investigating the association between hormonal contraceptive use and sleep quality. For instance, a wide variety of hormonal contraceptives are utilized by women who may change to other brands of contraceptive or birth control methods. In addition, most studies use subjective sleep measures, which may involve recall the information in the past. Through appraisal of published studies, our systematic review will inform the improvement in the design and implementation of future research in this field.

Conflict of Interest Disclosures: All the authors have declared no financial conflicts of interest. **Funding:** This research received no grant from any funding agency in the public, private or not-for-profit sector.

Acknowledgement: Dr. Chunxue Wang and Dr. Ning Zhang are supported by National Key Research & Development Program of China (No. 2016YFC1307200), National Key Research & Development Program of China (No. 2020YFC2005304), and Beijing Key Clinical Specialty Construction Project.

Author Contributions: JM, MC, XY, CW conceptualized and designed the protocol, drafted the initial manuscript and reviewed the manuscript. MC, XY, JM, QW, HK, and HR defined the concepts and search items, data extraction process as well as methodological appraisal of the study. MC, JM, QW, and XY planned the data extraction and statistical analysis. LT, CM, and NZ provided critical insights. All authors approved the final manuscript.

Table 1: Search Strategy for OVID Medline
Database(s): OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to March 7, 2021.

	#	Searches					
	1	exp contraceptive agents/ or exp hormonal contraception/ or exp contraception/ or fertility control.mp. or (fertiliz* adj3 inhibit*).mp. or exp birth control/ or exp family planning					
		services/ or desogestrel/ or nor pregnenes/ or progesterone congeners/ or exp ethinylestradiol/					
		or ethinyl estradiol.mp. or ethinylestradiol.mp. or dienogest.mp. or exp progestin/ or					
		progestin\$.mp. or progestogen.mp. or lynestrenol/ or norethindrone/ or levonorgestrel/ or					
		etynodiol diacetate.mp. or ethynodiol diacetate.mp. or norgestrel or mestranol.mp. or exp					
		mestranol/ or exp estradiol/ or estradiol.mp. or oetradiol.mp. or desogestrel.mp. or					
		norpregnene\$ or progestins).mp. or drospirenone.mp. or lynestrenol.mp. or					
		norethindrone.mp. or norgestrel.mp. or Etonogestrel.mp. or gestodene.mp. or					
		levonorgestrel.mp. or d-norgestrel.mp. or norgestimate.mp. or dienogest.mp. or					
		contracept*.mp. or birth control.mp. or family planning.mp. or intrauterine device.mp. or					
		"intra uterine device".mp. exp contraceptive devices, Female/ intrauterine system.mp. or					
		intrauterine contraceptive device.mp. or iud*.mp. or iucd*.mp. or exp Medroxyprogesterone/					
		or Depotmedroxyprogesterone.mp. or depo-medroxyprogesterone.mp. or					
		medroxyprogesterone.mp. or Depo-provera.mp. or depo provera.mp. or (vaginal or hormon*					
		or contraceptive) adj2 (ring or patch or injection).mp. or DPMA.mp.					
	2	Exp sleep/ or exp sleep-wake transition disorders/ or exp sleep deprivation/ or exp sleep					
		wake disorders/ or exp dyssomnias/ or fragmented sleep.mp. or insufficient sleep					
	syndrome\$.mp. or exp sleep latency/ or exp sleep hygiene/ or exp sleep arousal disorder/ or						
exp sleep disorder/ or sleep*.af. or insomnia\$.mp. or hypersomnia\$.mp. or "disorders of the state of the stat							
		excessive somnolence" or exp restless legs syndrome/ or restless legs syndrome.mp					
	3	(comment or letter or editorial or note or erratum or short survey or news or newspaper					
_		article or patient education handout or case reports or historical article).pt.					
_	4	Animal/ not human/					
_	5	3 or 4					
	6	1 and 2 not 5					
	7	Limit 6 to yr="1970-current"					

BM

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.	Enseignement Superieur (ABES) .	Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de
--	---------------------------------	---

Table 2: Search Strategy for OVID Embase Database: Embase 1974 to March 7, 2021. # Searches exp contraceptive agents/ or exp hormonal contraception/ or exp contraception/ or fertility control.mp. or (fertiliz* adj3 inhibit*).mp. or exp birth control/ or exp family planning services/ or desogestrel/ or nor pregnenes/ or progesterone congeners/ or exp ethinylestradiol/ or ethinyl estradiol.mp. or ethinylestradiol.mp. or dienogest.mp. or exp progestin/ or progestin\$.mp. or progestogen.mp. or lynestrenol/ or norethindrone/ or levonorgestrel/ or etynodiol diacetate.mp. or ethynodiol diacetate.mp. or norgestrel or mestranol.mp. or exp mestranol/ or exp estradiol/ or estradiol.mp. or oetradiol.mp. or desogestrel.mp. or norpregnene\$ or progestins).mp. or drospirenone.mp. or lynestrenol.mp. or norethindrone.mp. or norgestrel.mp. or Etonogestrel.mp. or gestodene.mp. or levonorgestrel.mp. or dnorgestrel.mp. or norgestimate.mp. or dienogest.mp. or contracept*.mp. or birth control.mp. or family planning.mp. or intrauterine device.mp. or "intra uterine device".mp. exp contraceptive devices, Female/ intrauterine system.mp. or intrauterine contraceptive device.mp. or iud*.mp. or iucd*.mp. or exp Medroxyprogesterone/ or Depotmedroxyprogesterone.mp. or depomedroxyprogesterone.mp. or medroxyprogesterone.mp. or Depo-provera.mp. or depo provera.mp. or (vaginal or hormon* or contraceptive) adj2 (ring or patch or injection).mp. or DPMA.mp. Exp sleep/ or exp sleep-wake transition disorders/ or exp sleep deprivation/ or exp sleep wake disorders/ or exp dyssomnias/ or fragmented sleep.mp. or insufficient sleep syndrome\$.mp. or exp sleep latency/ or exp sleep hygiene/ or exp sleep arousal disorder/ or exp sleep disorder/ or sleep*.af. or insomnia\$.mp. or hypersomnia\$.mp. or "disorders of excessive somnolence" or exp restless legs syndrome/ or restless legs syndrome.mp (editorial or note or letter erratum or short survey or abstract).pt. or abstract report/ or letter/ or case study/ animal/ not human/ or/3-4 exp female/ or female\$.mp. or women.mp. or woman.mp. (1 and 2 and 6) not 5 limit 7 to yr="1970-current"

Tabl	le 3: Search Strategy for Cochrane Central						
Database: Cochrane Central from inception to March 7, 2021.							
#	# Searches						
<u> </u>	MeSH descriptor: [Contraceptive Agents] explode all trees or MeSH descriptor: [Hormonal Contraception] explode all trees or MeSH descriptor: [Contraception] explode all trees or MeSH descriptor: [Contraception] explode all trees or fertilization inhibition or inhibition of fertilization or MeSH descriptor: [Family Planning Services] explode all trees or MeSH descriptor: [Desogestrel] this term only or MeSH descriptor: [Norpregnenes] this term only or MeSH descriptor: [Progesterone Congeners] this term only or MeSH descriptor: [Ethinyl Estradiol] explode all trees or ethinyl estradiol or ethinylestradiol or dienogest or MeSH descriptor: [Progestins] explode all trees or progestins or progestogen or MeSH descriptor: [Lynestrenol] this term only or MeSH descriptor: [Norgestrel] this term only or MeSH descriptor: [Estradiol] explode all trees or mestranol or MeSH descriptor: [Mestranol] explode all trees or norgestimate or norgestins or progestins or progesterone congeners adj2 synthetic or drospirenone or lynestrenol or norethindrone or norgestrel or Etonogestrel or gestogene or levonorgestrel or norgestimate or dienogest or contracept* or birth control or family planning or MeSH descriptor: [Intrauterine device] this term only or intrauterine device or intrauterine system or intrauterine contraceptive device or iud or d-norgestrel or iucd or depotmedroxy						
2	MeSH descriptor: [Sleep] explode all trees or MeSH descriptor: [Sleep-Wake Transition Disorders] explode all trees or MeSH descriptor: [Sleep Deprivation] explode all trees or MeSH descriptor: [Sleep Wake Disorders] explode all trees or MeSH descriptor: [Dyssomnias] explode all trees or MeSH descriptor: [Dyssomnias] explode all trees or ragmented sleep or insufficient sleep syndrome\$ or MeSH descriptor: [Sleep Hygiene] explode all trees or MeSH descriptor: [Sleep Latency] explode all trees or MeSH descriptor: [Sleep Arousal Disorders] explode all trees or sleep* or insomnia\$ or hypersomnia\$ or disorders of excessive somnolence or MeSH descriptor: [Restless Legs Syndrome] explode all trees or restless legs syndrome						
3	(comment or letter or editorial or note or erratum or short survey or news or newspaper article or patient education handout or case reports or historical article) pt						
Δ	MeSH descriptor: [Animals] explode all trees						
5	MeSH descriptor: [Humans] explode all trees						
6	3 and 4 not 5						
7	(1 and 2) not 6						
8	limit 7 to vr="1970-current"						

BMJ Open: first published as 10.1136/bmjopen-2020-045819 on 8 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES).

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

REFERENCES

 United Nations. Contraceptive Use by Method 2019: Data Booklet [Internet]. UN; 2019 [cited 2020 Jul 20]. Available from: <u>https://www.un-ilibrary.org/population-and-demography/contraceptive-use-by-method-2019_1bd58a10-en</u>

- van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception [Internet].
 2005 Sep;72(3)[cited 2021 March 1]:168–74. Available from: https://pubmed.ncbi.nlm.nih.gov/16102549/
 - Dean, Gillian; Schwarz, Eleanor Bimla (2011). "Intrauterine contraceptives (IUCs)". In Hatcher, Robert A.; Trussell, James; Nelson, Anita L.; Cates, Willard Jr.; Kowal, Deborah; Policar, Michael S. (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 147–191.
 - Lancel M, Faulhaber J, Schiffelholz T, Romeo E, Di Michele F, Holsboer F, et al. Allopregnanolone affects sleep in a benzodiazepine-like fashion. J Pharmacol Exp Ther [Internet]. 1997 Sep [cited 2020 Jul 20] ;282(3):1213–8. Available from: https://pubmed.ncbi.nlm.nih.gov/9316828/
 - Allada R, Cirelli C, Sehgal A. Molecular Mechanisms of Sleep Homeostasis in Flies and Mammals. Cold Spring Harb Perspect Biol [Internet]. 2017 Aug 1[cited 2020 Jul 20];9(8). Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538413/Schwartz MD, Mong JA.

- Estradiol modulates recovery of REM sleep in a time-of-day-dependent manner. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2013 May 15;305(3):R271–80.
- Bezerra AG, Andersen ML, Pires GN, Tufik S, Hachul H. Effects of hormonal contraceptives on sleep - A possible treatment for insomnia in premenopausal women. Sleep Sci [Internet]. 2018 Jun [cited 2020 Jul 20];11(3):129–36. Available from: <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201525/</u>
- 8. Léger D, Bayon V. Societal costs of insomnia. Sleep Med Rev. 2010;14(6):379-89.
- Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16(5):873-97; discussion 854.
- Gourineni R. Prognosis and complications. In: Attarian HP, ed. Clinical Handbook of Insomnia. 3rd ed. New York: Springer; 2017. p. 59-73.

BMJ Open

	(2011). Insomnia and the performance of US workers: results from the America inso
	<u>survey</u> . <i>Sleep</i> ; 34(9): 1161–1171.
12.	Ohayon, M.M., O'Hara, R., Vitiello, M.V. (2012). Epidemiology of restless legs
	syndrome: a synthesis of the literature. Sleep Medicine Reviews; 16(4): 283–295.
13.	Wimms, A., Woehrle, H., Ketheeswaran, S., Ramanan, D., Armitstead, J.
	(2016). Obstructive Sleep Apnea in Women: Specific Issues and Interventions. Bion
	Research International; 2016: 1764837.
14.	Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. In:
	Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al.,
	editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited
	2020 Sep 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK279054/
15.	Baker FC, Lee KA. Menstrual Cycle Effects on Sleep. Sleep Med Clin [Internet]. 20
	Sep[cited 2021 Mar 1];13(3):283–94.
16.	Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contracept
	and intrauterine contraceptive devices. Am J Obstet Gynecol [Internet]. 1999 Nov [
	2020 Jul 20] ;181(5 Pt 1):1263–9. Available from:
	https://pubmed.ncbi.nlm.nih.gov/10561657/
17.	Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ,
	Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial
	Cancers: A Systematic Review. Cancer Epidemiol Biomarkers Prev [Internet]. 2013
	1 [cited 2020 Jul 20];22(11):1931–43. Available from:
	https://pubmed.ncbi.nlm.nih.gov/24014598/
18.	Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral
	contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb
	Haemost [Internet]. 1997 Jul [cited 2020 Jul 20] ;78(1):327–33. Available from:
	https://pubmed.ncbi.nlm.nih.gov/9198174/
19.	van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The Risk of Deep Venous
	Thrombosis Associated With Injectable Depot-Medroxyprogesterone Acetate
	Contragentives or a Levenergestral Introvating Davies Arteriogalaresis Thrombos

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

and Vascular Biology [Internet]. 2010 Nov 1 [cited 2021 Jun 23];30(11):2297–300. Available from: https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.110.211482

- LeBlanc ES, Laws A. Benefits and Risks of Third-Generation Oral Contraceptives. J Gen Intern Med [Internet]. 1999 Oct [cited 2020 Jul 20];14(10):625–32. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1496751/
- 21. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. American Journal of Obstetrics and Gynecology [Internet] . 2017 Jun 1 [cited 2020 Jul 20] ;216(6):580.e1-580.e9. Available from: https://pubmed.ncbi.nlm.nih.gov/28188769/
- 22. Guida M, Rega A, Vivone I, Saccone G, Sarno L, Di Carlo C, et al. Variations in sleep associated with different types of hormonal contraceptives. Gynecol Endocrinol [Internet]. 2020 Feb [cited 2020 Jul 20] ;36(2):166–70. Available from: https://pubmed.ncbi.nlm.nih.gov/31311352/
- 23. Hachul H, Andersen ML, Bittencourt L, Santos-Silva R, Tufik S. A population-based survey on the influence of the menstrual cycle and the use of hormonal contraceptives on sleep patterns in São Paulo, Brazil. Int J Gynaecol Obstet [Internet]. 2013 Feb[cited 2020 Jul 20];120(2):137–40. Available from:

https://www.sciencedirect.com/science/article/abs/pii/S0020729212005619

- 24. Lundin C, Danielsson KG, Bixo M, Moby L, Bengtsdotter H, Jawad I, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology [Internet]. 2017[cited 2020 Jul 20];76:135–43. Available from: https://pubmed.ncbi.nlm.nih.gov/27923181/
- 25. Bezerra AG, Andersen ML, Pires GN, Banzoli CV, Polesel DN, Tufik S, et al. Hormonal contraceptive use and subjective sleep reports in women: An online survey. J Sleep Res [Internet]. 2020 Jan 27 [cited 2020 Jul 20] ;e12983. Available from: https://pubmed.ncbi.nlm.nih.gov/31989746/
- 26. Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., ... & Stewart, L. A. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews, 4(1), 1.

BMJ Open

	new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol.
	2016;69:225-34.
28	Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-
	2010, and changes in patterns of use since 1995. Natl Health Stat Report [Internet].2012
	Oct 18;(60):1–25.Available from:
	https://pubmed.ncbi.nlm.nih.gov/24988814/#:~:text=Use%20of%20intrauterine%20dev
	es%20as,current%2C%20most%20effective%20contraceptive%20method.
29	. Rao U, Hammen CL, Poland RE. Ethnic differences in electroencephalographic sleep
	patterns in adolescents. Asian J Psychiatr [Internet]. 2009 Mar 1;2(1):17-24. Available
	from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786078/
30	. Grandner MA, Patel NP, Gehrman PR, Xie D, Sha D, Weaver T, et al. Who Gets the Be
	Sleep? Ethnic and Socioeconomic Factors Related to Sleep Complaints. Sleep Med
	[Internet]. 2010 May;11(5):470–8. Available from:
	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861987/
31	. Nassaralla CL, Stanford JB, Daly KD, Schneider M, Schliep KC, Fehring RJ.
	Characteristics of the Menstrual Cycle After Discontinuation of Oral Contraceptives. J
	Womens Health (Larchmt) [Internet]. 2011 Feb 1 [cited 2021 Jun 24];20(2):169-77.
	Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643763/
32	. Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on
	mood: a critical review. Eur J Contracept Reprod Health Care. 2016 Oct;21(5):347-55.
33	. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep
	Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res
	[Internet]. 1989 May [cited 2020 Jul 20] ;28(2):193–213. Available from:
	https://pubmed.ncbi.nlm.nih.gov/2748771/
34	. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness
	scale. Sleep [Internet]. 1991 Dec [cited 2020 Jul 20];14(6):540-5. Available from:
	https://pubmed.ncbi.nlm.nih.gov/1798888/
35	. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an
	instrument based on ICD-10 criteria. Journal of Psychosomatic Research [Internet].

2000[cited 2020 July 20] ;48:555–60. Available from: https://pubmed.ncbi.nlm.nih.gov/11033374/

- 36. The Insomnia Severity Index: Psychometric Indicators to Detect Insomnia Cases and Evaluate Treatment Response [Internet]. [cited 2020 Jul 20]. Available from: <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079939/</u>
- 37. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric [Internet]. 2005 Aug [cited 2021 March 1];8 Suppl 1:3–63. Available from: https://pubmed.ncbi.nlm.nih.gov/16112947/
- 38. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 Aug 28 [cited 2020 Sep 28];366. Available from: <u>https://www.bmj.com/content/366/bmj.14898</u>
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 [cited 2020 Jul 20]; 28;366:14898. Available from: <u>https://pubmed.ncbi.nlm.nih.gov/31462531/</u>
- Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225-34.
- 41. Schünemann HJ, Brożek J, Guyatt G, Oxman A. GRADE handbook [Internet]. GRADE Handbook. 2013 [cited 2020 Sep 28]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html
- 42. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003 Sep 4;327(7414):557–60.
- 43. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.
- Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1998.
- 45. Chaimani A, Caldwell DM, Li T. Chapter 11: Undertaking network meta-analyses: Higgins JPT, Thomas J, Chandler J, et al., Cochrane Handbook for Systematic Reviews of Interventions. version 6.0 (updated July 2019) Cochrane, 2019

46. Caldwell DM, Welton NJ. Approaches for synthesising complex mental health interventions in meta-analysis. Evid Based Ment Health. 2016;19(1):16–21.

tor oper texter only

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

 Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page
		Reporting Item	Number
Title			ÿ
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	1
Update	<u>#1b</u>	If the protocol is for an update of a previous systematic review, identify as such	ي n/a د
Registration			
	<u>#2</u>	If registered, provide the name of the registry (such as PROSPERO) and registration number	300900
Authors			
Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the guarantor of the review	17
	For pe	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

	<u>#4</u>	If the protocol represents an amendment of a previously completed or	n/a
		published protocol, identify as such and list changes; otherwise, state	
		plan for documenting important protocol amendments	
Support			
Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	17
Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	n/a
Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any,	17
funder		in developing the protocol	
Introduction			
Rationale	<u>#6</u>	Describe the rationale for the review in the context of what is already	5-7
		known	
Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review will	7
-		address with reference to participants, interventions, comparators, and	
		outcomes (PICO)	
Methods			
Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study design, setting,	8-12
		time frame) and report characteristics (such as years considered,	
		language, publication status) to be used as criteria for eligibility for	
		the review	
Information sources	#9	Describe all intended information sources (such as electronic	7-8
	<u></u>	databases, contact with study authors, trial registers or other grey	, ,
		literature sources) with planned dates of coverage	
Search strategy	#10	Present draft of search strategy to be used for at least one electronic	18-22
Sourch sharegy	<u>#10</u>	database, including planned limits, such that it could be repeated	10-20
Q 1 1 1	// 1 1		10.10
Study records - data	<u>#11a</u>	Describe the mechanism(s) that will be used to manage records and	12-13
management		uata unougnout the review	
Study records -	<u>#11b</u>	State the process that will be used for selecting studies (such as two	12-13
selection process		independent reviewers) through each phase of the review (that is,	
		screening, eligibility and inclusion in meta-analysis)	
Study records - data	#11c	Describe planned method of extracting data from reports (such as	12-13
		r	

			BMJ Open	Page 30 of 29
1 2 3 4 5 6 7 8 9 10 11 12	collection process		piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	BMJ Open
	Data items	<u>#12</u>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	12-13 first publishee
	Outcomes and prioritization	<u>#13</u>	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	12-13 Protec
13 14 15 16 17	Risk of bias in individual studies	<u>#14</u>	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	6/bmjopen-2020 13by copyrigi 13
18 19 20 21	Data synthesis	<u>#15a</u>	Describe criteria under which study data will be quantitatively synthesised	14-15 14-15 14-15 14-15
22 23 24 25 26 27 28	Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall's τ)	n 8 October 2021. D Enseignemei g for uses related t
29 30 31	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	o wnloadec o text and 14-15
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the type of summary planned	14-15 data minin
	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	g, Al trainin
	Confidence in cumulative evidence	<u>#17</u>	Describe how the strength of the body of evidence will be assessed (such as GRADE)	.bmj.com/ on J 19, and similar
	The PRISMA-P elab Attribution License C <u>https://www.goodrep</u>	oration CC-BY. orts.org	and explanation paper is distributed under the terms of the Creative Commons This checklist was completed on 29. June 2021 using (, a tool made by the <u>EQUATOR Network</u> in collaboration with <u>Penelope.ai</u>	June 11, 2025 at Agence Bibliographique de r technologies.